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Statins are commonly used to lower cholesterol levels for cardiovascular 
disease (CVD) patients in the primary and secondary prevention of acute events. 
26% of American adults over age 40 used statins in 2012 and an estimated 26.4 
million U.S. adults could benefit from statin use. Although statins are generally 
well tolerated and show a relatively good safety profile, concerns have been 
raised regarding statin associated adverse events (AEs) especially muscle 
related events, leading to medication non-adherence and discontinuation. 
Besides, AEs are often caused by potential drug-drug interactions (DDIs) which 
are responsible for up to 2.8% of hospital admissions1. Among CVD patients, 
combination therapy of statins and other medications is highly likely, which 
results in altered absorption, distribution, metabolism, or excretion of statins and 
thus causes adverse events. Traditional AE management approaches may 
include a statin therapy holiday, lower statin dosage, an alternative statin agent, 
or non-statin cholesterol-lowering therapy. Currently, there are no tools to 
effectively predict and reduce the risk of AEs prior to statin therapy initiation. In 
addition, no population-based studies have focused on a specific statin and a 
specific interacting drug and differentiated their risks among different study time 
periods. 
In this study, we investigated the effect of combination therapy of 
simvastatin and several pre-defined high risk interacting drugs, which belong to 
cytochrome P450 (CYP) 3A4 and/or organic anion transporting polypeptide 
(OATP) inhibitors, in CVD patients who used simvastatin for secondary 
	 v	
prevention. This could provide some evidence and recommendations for selected 
interacting drugs used in CVD patients. In addition, we aimed to build a model to 
predict statin-associated AEs that may reduce the risk of statin associated 
adverse events and the rate of statin therapy cessation. Several machine 
learning methods were applied, such as generalized linear model (GLM), support 
vector machine (SVM), decision tree, random forest, and artificial neural network 
(ANN). Models were developed and compared for their performance. The best 
model was selected based on the best performance.  
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Chapter 1 Introduction 
Chapter 1 provides an overview of current statin use, including drug class 
review, current use of statins in the clinical setting, problems and possible 
solutions for statins adherence issues, and drug-drug interactions (DDIs) review. 
The significance and the specific aims of this study will also be discussed. 
1.1 Overview of current statin use 
1.1.1 Brief drug class review 
Statins are a class of drug that inhibit 3-hydroxy-3-methyl-glutaryl-
coenzyme A (HMG-CoA) reductase, the pivotal rate-controlling enzyme in the 
production of cholesterol. Seven statin agents currently available in the United 
States (U.S.) were included in this project. 
Table 1- 1 Statin agents that are approved by Food and Drug Administration 
Generic Name of Statins Brand Name 
Year of FDA 
Approval 
Lovastatin Mevacor®, Altoprev® 1987 
Pravastatin Pravachol® 1991 
Simvastatin Zocor® 1991 
Fluvastatin Lescol®, Lescol® XL 1993 
Atorvastatin Lipitor® 1996 
Rosuvastatin Crestor® 2003 
Pitavastatin Livalo® 2009 
FDA = Food and Drug Administration 
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Table 1-1 shows all seven statin agents that are approved for use by the 
Food and Drug Administration (FDA). Lovastatin was the first statin introduced in 
the U.S. Pitavastatin, which is known as Livalo®. Pitavastatin is the latest statin 
to be introduced to the market. Cerivastatin was not included because it was 
withdrawn from the market in 2001, due to its high risk of fatal rhabdomyolysis 
events.  
1.1.2 Current and emerging statin use for cardiovascular disease 
patients 
High blood cholesterol is an important risk factor contributing to the 
development of cardiovascular disease (CVD), the leading cause of death 
worldwide. Reducing the level of cholesterol can help to reduce the chance of 
developing CVD as well as to prevent the recurrence of acute events in those 
with known disease2,3. Statins are highly effective drugs for lowering low-density 
lipoprotein (LDL) cholesterol, non-high-density lipoprotein cholesterol, and 
apolipoprotein B levels in plasma, all of which are key contributors to CVD 4,5. 
Extensive clinical trials and studies support beneficial effects of this class of 
drugs for the secondary prevention and treatment of atherosclerotic CVD6 in 
patients who are at very high risk of developing CVD or have had heart diseases 
such as myocardial infarction and stroke. Prior clinical studies5,7 also suggested 
that statins may be beneficial for the primary prevention of coronary heart 
disease in patients without a history of CVD. Although other non-statin therapies 
are alternatives to reduce cholesterol, most of them do not have a comparable 
atherosclerotic cardiovascular event and mortality reduction as compared with 
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statins. Proprotein convertase subtilisin/kexin type 9 serine protease 
(PCSK9) inhibitors are a new type of cholesterol drug. A new study 8 published in 
2018 showed that risk of major adverse CVD events was lower among those who 
receive PCSK9 added to statin therapy than among those who treat with statin 
alone. However, PCSK9 inhibitors are newer and have less long-term safety 
data. In addition, they are very expensive compared to statins. Thus, the number 
of patients who received PCSK9 is much smaller than statin users. 
A study from the U.S. Department of Health and Human Services showed 
that during the 2007–2010 time period, approximately 47% of Americans who 
were more than 65 years old took statins or other cholesterol-lowering drugs 9. 
This usage rate of cholesterol-lowering drugs has increased approximately 7-fold 
since 1988–1994, due in part to the introduction and acceptance of statin drugs.  
1.1.3 Problems and previous solutions for therapy with statins 
Although statins are generally safe for the majority of individuals, it has 
been reported that more than 50% of patients discontinued statin medication 
within 1 year after treatment initiation 10. Among the various reasons that lead to 
statin discontinuation or statin intolerance, adverse events (AEs) is the primary 
reason for such discontinuation 11,12. Statin-associated AEs13–15 include minor 
side effects such as muscle symptoms, digestive problems, dizziness, and some 
rare but clinically important events such as myopathy16,17, rhabdomyolysis 18, 
liver events 17,19–21, acute kidney injury17,22,23, drug poisoning events24, and 
increased risks for hyperglycemia and cognitive effects 25,26. One study27 showed 
that approximately 17%  of statin users had an adverse event during their study 
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period (from 2000 to 2008). The consequence is that important clinical and 
treatment benefits of statin use for lowering plasma cholesterol levels (and 
therefore risk of primary and secondary cardiovascular events) are frequently lost 
due to discontinuance of statin treatment following occurrence of AEs, leading to 
increased cholesterol levels and increased cardiovascular events28. 
Not every statin user will have AEs, but some patients may have a greater 
risk of developing statin AEs than others. Patient-related risk factors include older 
patients, small body frame, a history of specific diseases (myopathy, creatine 
kinase elevation, muscular symptoms, liver, and kidney), alcohol use, grapefruit 
juice consumption (>1 quart/day), major surgery in the perioperative period 29 
female patients 11, and excessive physical activity 30. Treatment-related risk 
factors include high-dose statin therapy and combination therapy of statins and 
other medications which are either substrates or inhibitors of cytochrome P450 
(CYP) 3A4) 31. 
Typical strategies to manage and control statin-related AEs include 
reducing statin dosage, using an alternative statin agent or non-statin 
cholesterol-lowering therapy, switching to nondaily dosing statin regimen, using a 
statin holiday, or dietary intervention32–34. In practical settings, these traditional 
approaches control AEs after the AE occurrence, leading to statin treatment 
discontinuation. This could be problematic. For example, switching to a lower 
statin intensity can reduce AE risk, but may also lessen the reduction in 
atherosclerotic cardiovascular disease risk 34. Switching to non-statin therapy is 
problematic as well, given that many non-statins have worse AE profiles and less 
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effective than statins at lowering LDL cholesterol35. Proactive prevention of statin 
adverse events has not been well studied. Individuals may have different 
responses to individual statins at a specific dosage. So when physicians 
prescribe statins, the decision should not only depend on the cholesterol levels 
but also the patients’ characteristics.  
1.1.4 Drug interactions 
Statin interactions, which include statin-food and statin-drug interactions, 
are a common cause of AEs. Most of the statins are metabolized by CYP450 
enzymes. Simvastatin, atorvastatin, and lovastatin are metabolized by CYP3A4. 
Fluvastatin and rosuvastatin (to a lesser extent) are substrates for CYP2C9. 
Pravastatin and pitavastatin are minimally metabolized by CYP450 enzymes. In 
addition, the organic anion transporting polypeptide (OATP) 1B1 is known to 
transport all statins from plasma into hepatocytes for metabolism and 
elimination36–42. Hence, food or drugs that potentially are substrates for or inhibit 
CYP3A4 enzyme or/and inhibit OATP transporters may increase the plasma 
concentration of statins and thus increase the risk of adverse events. 
The most common statin-food interaction, especially for simvastatin, 
lovastatin, and atorvastatin, is grapefruit juice which contains an organic 
chemical compound -furanocoumarins that can inhibit the CYP3A4 enzyme and 
increase statin levels in plasma43. Grapefruit also affects OATP transporters44. 
Statin-drug interactions are another type of interaction. Many CVD 
patients may need statins in combination with other therapies, especially in those 
who have multiple comorbidities, and those at high CVD risk who cannot achieve 
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optimal therapeutic benefits from statin monotherapy45–47. In one study, more 
than 20% of statin users were detected with potential statin DDIs48. In this study, 
several interacting medications with the highest DDI risk were included. These 
medications were selected by clinical expert review after carefully screening 
available DDIs resources including drugs.com, Lexicomp, Epocrates, and one 
published literature49. Table 1-2 shows the mechanisms of interaction that these 
medications have with simvastatin, lovastatin, and atorvastatin. Antibiotics such 
as clarithromycin, erythromycin, and telithromycin are strong inhibitors of the 
CYP3A4 and OATP1B1. Studies and case reports50–54 have shown that 
coprescription of a statin agent with clarithromycin, erythromycin, or telithromycin 
are associated with a higher risk of rhabdomyolysis, acute kidney injury, and/or 
all-cause mortality. Antifungals medications such as itraconazole, ketoconazole, 
and posaconazole are potent CYP3A4 inhibitors. Co-administration of those 
medications with statins could induce rhabdomyolysis and renal injury 55–57. 
Nefazodone58 (antidepressant drug), boceprevir59 (protease inhibitor for hepatitis), 
and danazol60 (androgenic hormone) are also potent CYP3A4 inhibitors. Many 
case reports showed patients who were treated with those drugs while on 
concomitant statins could possibly develop an increased risk of rhabdomyolysis 
or myopathy 59,61–64. Cyclosporine40,65 (immunosuppressant) and cobicistat66 
(pharmacokinetic enhancer) are both CYP3A4 and OATP1B1 inhibitors. 
Therefore, coadminstration of those with statins is contraindicated because of the 
high risk of rhabdomyolysis or kidney injury 67–69. Gemfibrozil40, a fibric acid agent, 
is a well-known OATP inhibitor that does not alter CYP3A4 activity. The 
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combination therapy of gemfibrozil and statins is also considered a 
contraindicated treatment70–72.  
Table 1- 2 The inhibitors of CYP3A4 or OATP1B1 
Drugs CYP3A4 inhibitor OATP1B1 inhibitor 
Antibiotics (clarithromycin, 
erythromycin, and telithromycin) 
√ √ 
Antifungals (itraconazole, 
ketoconazole, and posaconazole) 
√ X 
Cyclosporine √ √ 
Cobicistat √ √ 
Nefazodone √ X 
Boceprevir √ X 
Danazol √ X 
Gemfibrozil X √ 
Note:  CYP = cytochrome P450;  
OATP = organic anion transporting polypeptide 
1.2 Significance 
This dissertation addresses an important issue - statin associated adverse 
events in CVD population- which were used to study an important problem of 
drug therapy optimization. We focused on general statin AEs associated AEs as 
well as those caused by combination therapy of simvastatin and several pre-
defined high risk interacting drugs (CYP3A4 and/or OATP inhibitors).  
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We utilized existing observational data to evaluate statin AEs. 
Randomized controlled trials often have limited generalizability because of 
rigorous inclusion and exclusion criteria for selecting patients.  The observational 
dataset, on the other hand, allows a pragmatic research approach, including 
patients who have more complicated situations than those in clinical trials. 
Medication and clinical strategies are not controlled by the researchers’ 
experimental design and can reflect the actual clinical practice patterns without 
restricted conditions and thus, facilitate high generalizability.  
Healthcare machine learning methods were integrated to manage and 
analyze the large volume of population-based data. The current reactive 
approach to manage statin AEs is problematic because it only initiated after AEs 
have occurred. The proactive strategy for statin prescription decision lacks a 
working approach outside of a trial and error prescribing approach. Few previous 
studies focused on the prediction of statin associated AEs. This dissertation 
focused on this aspect by developing predictive model, which is capable of 
integrating complex patient characteristics as predictors, for predicting statin 
associated adverse events. The results from big data analysis can provide 
additional information and support along with experts’ personal experience for 
medical decision making. This model is the first step toward of overcoming the 
clinical challenges on statin associated AEs reduction and will be adapted to 
develop a decision-support system - the Personalized Statin Treatment Plan 
platform, to support proactive statin prescription decisions. This use case can 
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also be expanded to other medication management issues to reduce AEs and 
improve the medication adherence.  
1.3 Specific Aims 
This dissertation hypothesizes that statins combined with medications that 
have known DDIs with statins would cause more adverse events and more 
intense medical follow-up. In addition, the development of an adverse events 
prediction model could identify the risk of adverse events with statins and 
interacting medications and can better assist clinicians to estimate the risk of 
adverse events. The objectives of this dissertation are to investigate the adverse 
events among statin users in CVD patients in order to provide clinical evidence of 
AEs risk comparison, estimation, and management, as well as to develop a 
predictive model that can be used in the future to aid clinicians in selecting an 
optimal statin treatment plan for individual patients to minimize the risk of 
adverse events. To address these objectives, three specific aims were proposed: 
1) To evaluate the risk of adverse events in CVD patients who initiated 
statin agents for secondary prevention of CVD. 
2) To evaluate the effect of combination use of simvastatin with known 
high-risk drugs which are inhibitors of CYP3A4 and/or OATP transport 
in CVD patients. 
3) To develop a predictive model using machine learning methods for the 
occurrence of statin associated adverse events in CVD patients. 
1.4 Thesis outline 
The entire project consists of four components (summarized in Figure 1-1).  
	 10	








Note: OLDW = OptumLabs® Data Warehouse   
ML = machine learning    

























Chapter 2 Background 
In this chapter, background knowledge including secondary data analysis, 
data source, machine learning algorithms, cross validation, and model 
performance metrics will be introduced. 
2.1 Emerging Models for Secondary Data Analysis 
The use of secondary data analysis (SDA) is an important resource for 
population-based healthcare research. This, in part, can be attributed to 
improvements in access to large scale, complex datasets previously described 
as “big data”.   
A number of large databases are available to researchers today.  These 
include public databases such as the Medicare Claims Public Use files (588,415 
lives annually)73 , the Centers for Disease Controls National Center for Health 
Statistics (42,000 households per year)74 and the Agency for Healthcare 
Research and Quality Healthcare Cost and Utilization Project (7 million hospital 
stays annually)75.  These databases contain a mix of insurance claims data as 
well as survey and census data. Other databases may include grant funded 
projects such as the Clinical Translational Science Institute (62 medical 
institutions in 32 states)76, the Patient Centered Outcomes Research Institute (47 
million lives of electronic health record and patient reported outcomes data)77, 
and the Healthcare Cost Institute (40 million lives annually of insurance claims 
data) 78.  Finally, with passage of the Health Information Technology for 
Economic and Clinical Health Act in 2009, health systems have created large 
scale data repositories of clinical and administrative data from the 
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implementation of electronic health records.  These data repositories, fed by 
multiple hospitals within an integrated health system, can contain data on millions 
of patient records. 
2.2 Data Source 
An emerging research model is the development of partnerships, which 
make available “primary” use of data for SDA. A pioneer in this new model is 
OptumLabs. OptumLabs is an open, collaborative research and innovation center 
founded in 2013 as a partnership between Optum and Mayo Clinic with its core 
linked data assets in the OptumLabs Data Warehouse (OLDW). It comprises 
more than 20 years of data and approximately 200 million patient records in 
this database with more new patients and patient information being added and 
updated periodically providing additional insights. The database contains de-
identified, longitudinal health information on enrollees and patients, representing 
a diverse mixture of ages, ethnicities and geographical regions across the United 
States. The claims data in OLDW includes medical and pharmacy claims, 
laboratory results and enrollment records for commercial and Medicare 
Advantage enrollees. The EHR-derived data includes a subset of EHR data that 
has been normalized and standardized into a single database79.  
The administrative claims data includes medical claims, pharmacy claims 
(both pharmacy and pharmacy Part D data), and enrollment information which 
includes cost data (patient and health plan paid amount). Administrative data is 
linkable to health risk assessment, SES information, lab test results (focus on 
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serum, urine, and blood-based labs), and supplemental oncology data included 
in OLDW.  
The medical claims data are collected from all health care sites (e.g., 
inpatient hospital, outpatient hospital, emergency room (ER), physician’s office, 
and surgery center) for services including specialty, preventive and office-based 
treatments. It has one line of data for each service claim and includes data such 
as date of service, diagnosis codes, procedure codes, site of service codes, 
present on admission (POA) codes, patient and health plan paid amounts, and 
provider specialty codes. While the medical claim data is updated monthly, 
researcher typically allow 4-6 months to account for claim adjudication.  
The pharmacy claims data is comprised of outpatient prescription fills. 
They are submitted by pharmacies, including retail, mail order, hospital discharge, 
and specialty pharmacies. Pharmacy Part D claims are stored in another table 
which only includes prescription claims for Medicare Part D plan enrollees. The 
pharmacy claims data includes drug related information (e.g., medication name, 
dosage form, drug strength, fill date, and days of supply). While pharmacy data is 
updated monthly, researchers typically allow 8 weeks to account for adjudication. 
Using administrative data for healthcare research presents a number of 
benefits.1) It contains a large number of patients that can provide the opportunity 
and possibility to study low incidence events. 2) Its ready availability provides the 
possibilities of obtaining reliable large sample size of data at low cost compared 
with traditional censuses and questionnaires. 3) Information included in 
administrative data are not easily obtained and reported by individuals or 
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elsewhere. Despite advantages, several limitations also need to be considered. 1) 
This dataset does not represent the entire US population. For example, it does 
not include administrative claims for Medicaid plans. Clinical activities for patients 
who have Medicaid plans are captured in clinical data. 2) Clerical errors may 
exist in claims data including incorrect or missing data. 3) Diagnosis and 
procedure codes cannot reliably infer disease severity. 4) These data do not 
capture all the medical events. Claims-based reporting mainly exists to ensure 
that reimbursement is obtained by providers for medical services. Some events 
may not be tied to reimbursement. For example, a patient calling their provider, 
stopping therapy, not seeking medical attention may not be captured reliably. 5) 
Only prescribed medications covered under the benefit plan are included. Over-
the counter (OTC) medications are not reliably covered and thus many patients 
may have missing data in terms of OTC medications. In addition, medications 
that patients choose to pay out-of-pocket, herbal therapies or supplements are 
generally not included in claims data. This can potentially limit research accuracy. 
6) Drug information is extracted from prescription records, but we cannot 
guarantee patients actually take the prescribed drugs. 7) The lab results in 
OLDW claims data are incomplete and underrepresented in the data set. While 
this varies by test, lab results are available for approximately 40% of patients with 
a laboratory test. However, the presence of a lab result for an individual does not 
mean that all of their lab results are included. These data only contain outpatient 
laboratory values, with the most common sample types being serum, urine, and 
	 15	
blood-based samples.  Also, results for lab tests processed outside of certain 
clinical laboratories are not available in the database. 
2.3 Machine learning algorithms 
Machine learning methods provide powerful approaches to discover 
hidden patterns from a large amount of data and are primarily used for prediction 
and exploratory studies. Supervised learning and unsupervised learning are two 
main types of machine learning algorithms. They are distinguished by whether 
training data has known output variables (also known as results, labels, or 
outcomes). For example, to predict whether a patient has hypertension, patient 
traits (e.g., age, gender, race, medical history, and lab tests) are referred to as 
input variables/features/predictors and disease information (whether a patient 
has hypertension) is referred to as output variable. Models. Supervised learning 
is applied when training data has both input and output variable. It trains a model 
on these known input and output variables and predicts future outputs on new 
patients. If only input variables are available, then unsupervised learning 
methods, which finds hidden patterns in the input data, should be applied. 
Broadly speaking, supervised learning includes categories of classification and 
regression, while unsupervised learning includes categories of association rule 
learning and clustering analysis.  For this project, supervised learning methods 
were applied since the outcomes variable (whether patients had AEs) was 
available for each individual in our training data.  
Five classic supervised learning classification models were initially 
investigated, including generalized linear models (GLMs), support vector 
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machine (SVM), decision tree, random forest, and artificial neural networks 
(ANN).  
2.3.1 GLMs 
GLMs80 represent a broad class of regression models including but not 
limited to linear regression, logistic regression, and Poisson regression. GLMs 
allow researchers  to generalize the linear regression approach to accommodate 
many types of response variables (e.g., continuous, binary, proportions, count, 
and positive count data).  
In a GLM, 
𝑦! = 𝛽! + 𝛽!𝑥!! +⋯+ 𝛽!𝑥!" + 𝜖! 
𝑦! is the response variable which is modeled by a linear function of explanatory 
variables 𝑥!(𝑗 = 1,…𝑝) plus an error term. It is made up of a linear predictor: 
𝜂! = 𝛽! + 𝛽!𝑥!! +⋯+ 𝛽!𝑥!" , and two functions: 1) a link (mean) function that 
specifies how the expected value of response variable, 𝐸 𝑌! = 𝜇!, relates to the 
linear predictor: 𝑔 𝜇! = 𝜂! , and 2) a variance function that specifies the 
associations between the variance and the mean: var (Y!) =  ϕV(µ) where the 
dispersion parameter ϕ is a constant.  
Some common regression model specifications include 1) linear model 
containing an intercept and linear term for each predictor, 2) interactions model 
containing an intercept, linear term for each predictor, and all products of pairs of 
distinct predictors (no squared terms), 3) pure-quadratic model contains an 
intercept term and linear and squared terms for each predictor, and 4) quadratic 
model containing an intercept term, linear and squared terms for each predictor, 
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and all products of pairs of distinct predictors. Table 2-1 shows some examples 
of these models. 
Table 2- 1 Model functions of different model specifications 
Model specification 
Model functions  
(Assume has only two predictors 𝐱𝟏 and 𝐱𝟐) 
Linear 𝑦 ~ 𝑏! + 𝑏!𝑥! + 𝑏!𝑥! 
Interaction 𝑦 ~ 𝑏! + 𝑏!𝑥! + 𝑏!𝑥! + 𝑏!𝑥!𝑥! 
Pure-quadratic 𝑦 ~ 𝑏! + 𝑏!𝑥! + 𝑏!𝑥! + 𝑏!𝑥!! + 𝑏!𝑥!! 
Quadratic 𝑦 ~ 𝑏! + 𝑏!𝑥! + 𝑏!𝑥! + 𝑏!𝑥!! + 𝑏!𝑥!! + 𝑏!𝑥!𝑥! 
 
The assumptions of GLM include: 1) the response variables are 
independently distributed; 2) linear relationship between the transformed 
response in terms of the link function and the explanatory variables; 3) errors 
need to be independent but not normally distributed. 
In GLM, response variables do not need to be transformed to have a 
normal distribution. The choice of link function is separate from the choice of 
distribution. Table 2-2 shows the choices of link functions for difference data 
types. Table 2-3 shows the common link functions. 
Table 2- 2 Common data types with model distribution, variance function, and 
link types 
Data type Model 
distribution 
Variance 




can be used 
Continuous data Normal 1 Identity Log, inverse 
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Binary data Bernoulli µ!(1− µ!) Logit Probit, log 
Count data Poisson µ! Log Identity, 
square root 
Positive counts Gamma µ! Inverse Log, identity 
Note: 𝜇! is the expected value of the response variable. 
Table 2- 3 GLMs common link functions 
Link type Link functions, 𝒈(𝝁𝒊) 
Identity link 𝜇! 








Square root link 𝜇! 
Probit link 𝜙!!(𝜇!) 
Note:  𝜇! is the expected value of the response variable.  
𝜙  is the cumulative distribution function (CDF) of the standard-
normal distribution. 
2.3.2 Support Vector Machine 
SVM81 is one of the top-ranked algorithms that can be used for 
classification and regression analysis with good generalization performance and 
good ability to solve a wide range of problems. It performs classification work by 
drawing a separating line which is known as a hyperplane82. The objective of 
SVM is to find a hyperplane in a N-dimensional (N is the number of features), 
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given labeled training data, that distinctly categorizes the data points into two 
classes by maximizing the margin (decision boundary) around the hyperplane. 
Generalization error improves when the margin is larger. Data points that are 
closest to the hyperplane are called support vectors. For example, in Figure 2-1, 
the best hyperplane is the one whose distance to the nearest element of each 
class (blue circle or red square) is the largest. Data points that located on either 
side of the hyperplane are identified as different classes. In 2-dimensional space, 
a hyperplane is a line. In 3-dimensional space, a hyperplane is a plane. As the 
number of features increase, it becomes hard to imagine the hyperplane. 
 
Figure 2- 1 SVM maximum margin and optimal hyperplane 
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Figure 2- 2 Kernel function for non-linearly separable data points 
However, sometimes data points are not linearly separable in the original 
dimensional space. A kernel function is a method that uses a linear classification 
method to solve a non-linear problem. The kernel function finds a linear decision 
boundary by mapping the original non-linear data points into a higher 
dimensional space. In Figure 2-2, it shows an example that the two classes (blue 
dots and red dots cannot be separated linearly in the original 2-dimensional 
space. However, they can be separated by a plane when those data points are 
projected in a higher dimension (a 3-dimensional space in this example). Kernel 
functions can be viewed as similarity functions that compute the similarity score 
(a dot product) of two vectors 𝑥!  and 𝑥!  in a higher dimensional space. The 
common kernel functions include linear kernel, radial basis function (RBF) kernel, 
and polynomial kernel. Table 2-4 shows the formula for different types of kernels. 
The linear kernel works when data points are linearly separable. The RBF and 




Table 2- 4 Common kernel functions for SVM 
Type of kernel  Kernel function, 𝐾 𝑥! , 𝑥!  
Linear kernel 𝑥! ∙ 𝑥! 
RBF kernel exp −𝛾 𝑥! − 𝑥!
!
     (𝛾 > 0) 
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Polynomial kernel (𝑥! ∙ 𝑥! + 1)! 
Note: RBF =  radial basis function 
          𝐾 is the kernel function.  
 x is input variables. 
 𝛾  is a hyperparameter. 
d is the degree of the polynomial: d=1 leads to a linear separation, d=2 
gives a quadratic kernel, and higher-degree kernels allow a more flexible 
decision boundary. 
SVM is an effective tool in high dimensional spaces, such as document 
categorization, and generalizes well with high-dimensional data. The ability to 
apply new kernels allows substantial flexibility for the decision boundaries, 
leading to greater classification performance.  
2.3.3 Decision tree 
The decision tree model83 is constructed in the shape of a tree structure 
representing the hierarchical organization with multiple branches and levels. 
Figure 2-3 shows an example of decision tree model. The topmost node, 
(‘age>30’) is called the root node. Node without descendants, such as ‘minivan’ 
and ‘sports car’, is called a leaf node, which represents a classification. Other 




Figure 2- 3 Demonstration of a decision tree 
Decision trees can grow very large and complicated. It’s easy to create an 
over-complex classification tree that may fit the training data well, but may do a 
poor job of classifying new values. This is called overfitting. The process of 
reducing the size of the tree can reduce model complexity and computation time 
and is useful for preventing overfitting. Mechanisms such as setting the minimum 
number of leaf node observations and the maximum number of splits are 
necessary to avoid this problem. The minimum number of leaf node observations 
(N) requires that each leaf has at least N observations per leaf node; further 
splitting of nodes is stopped when the number of observations in the node is 
lower than N. The maximum number of splits (M) stops further splitting of nodes 
when the number of split nodes has been reached resulting a tree with M or 
fewer split nodes. These are called model hyperparameter, a parameter need to 
be initialized before training a model, which are used to optimize the model 
performance. For example, kernel function in SVM, value of K in k-nearest 
neighbor (KNN), depth of tree in decision trees, and number and size of the 
hidden layers in ANN. 
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In a dataset, there are many potential variables that can be selected as 
root node or split node(s). Measures of node impurity are used for selecting the 
best split. Gini index is a metric to measure how often a randomly chosen 
element would be incorrectly identified. A variable with lower Gini index is 
preferred. Gini index for a given node t is calculated as 
𝐺𝑖𝑛𝑖 𝑡 = 1− [𝑝(𝑗|𝑡)]!
!
 
𝑝(𝑗|𝑡) is the relative frequency of class j at node t.  
Another well-known measurement is called entropy which is similar to the 
Gini index computation. Entropy at a given node t is calculated as 
𝐸𝑛𝑡𝑟𝑜𝑝𝑦 𝑡 = − 𝑝(𝑗|𝑡)𝑙𝑜𝑔 [𝑝(𝑗|𝑡)]
!
 
2.3.4 Random forest 
Unlike a decision tree which builds only one tree, a random forest builds 
multiple decision trees. It can solve the overfitting problem of a decision tree and 
run efficiently on large data. Each tree gives a classification (votes for that class). 
A new object is classified to the class that has the most votes over all the trees. 
For example, in Figure 2-4, if class A has more votes than class B from the trees, 
then this new instance is classified as class A. The training set for each tree is 
created from random resampling of data in original training set with replacement. 
Therefore, some data could be duplicated and some data could be missing in 
each training set. This process is called bootstrapping. The size of each training 
set is the same as the original training set.  
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Figure 2- 4 Demonstration of random forest classification 
There are some hyperparameters need to be considered when developing 
random forest. Tree number is the number of trees the model builds before 
taking the majority voting. In general, a higher number of trees increases the 
performance and makes the predictions more stable, but it also slows down the 
computation. The other hyperparameter is the number of features (NumFeature) 
randomly selected when splitting a node. If all features are used to build each 
tree, then this creates a risk of correlation between trees and increases bias in 
the model. Thus, random forest chooses only a subset of the features at each 
split to reduce the issue of correlation between trees. As the number of selected 
features goes up, the strength of the individual trees increases. However, 
reducing the number of features leads to a lower correlation among the trees and 
increases the entire model strength.  
Out-of-bag (OOB) error is a method of measuring the prediction error 
of random forests. Suppose the original training data is T and the number of 
trees are determined as N. N training sets, denoted as {T!,T!,… ,T!}, are created 
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for N trees {𝐾!,𝐾!,… ,𝐾!}. Each of these training set is called a bootstrap dataset. 
For each data point 𝐷!  in the original training set T, select all the bootstrap 
datasets that does not contain the data point 𝐷!. This set of bootstrap datasets is 
called OOB samples. Each data point in the original training set has one set of 
OOB samples. OOB error is the mean prediction error on each training data point 
𝐷! 84. This can be used to select tree number. 
2.3.5 Artificial Neural Network 
ANNs are a set of algorithms that were inspired by the human nervous 
system and work in a similar way to the human brain does. They can be used to 
extract intricate patterns, discover the relations between the input and output 
variables, and solve complex problems. ANNs are an assembly of interconnected 
nodes and weights with three layers: input layer, hidden layer, and output layer 
(see Figure 2-5). The nodes, which are also known as neurons, are 
interconnected to process complex information. Each neuron consists of input, 
weight, and transfer function. A weight is associated with each input and is given 
to each hidden layer. It represents the strength of its relationship with the output. 
The hidden layer transforms the input into something that the output layer can 
use. ANNs process records one at a time and learn by comparing their results 
with the true labels. As the model develops, the errors from the initial 
classification (initialized weights) of the first record are used to update the 
weights and modify the networks algorithm for further iterations. Model accuracy 
and generalize abilities are improved while training. At last, the output layer sums 
up each of its input value according to the weights of its links.  
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Figure 2- 5 Artificial neural network components 
A learning algorithm is applied to train the network between 
interconnected neurons. Three commonly used learning algorithms include 
Bayesian regularization (BR) algorithm, Levenberg-Marquard (LM) algorithm, and 
scaled conjugate gradient (SCG) algorithm. BR updates weight according to BR 
optimization which minimizes a combination of squared errors and weights, and 
then determines the correct combination so as to produce a network that 
generalizes well 85. LM updates weight according to LM optimization that is 
designed to reducing error function with a fast and stable convergence 86. SCG 
updates the weight and bias values based on conjugate directions without 
performing a line search at each iteration 87. LM is recommended for most 
problems. For some noisy and small problems, BR can take longer but obtain a 
better solution88. SCG is recommended for large problems as it uses gradient 
calculations which are more memory efficient than the other two algorithms 88. 
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The advantages and disadvantages of the above machine learning 
algorithms are shown in Supplementary Table 1.  
2.4 Cross validation 
Cross-validation (CV) is a common strategy that is used for training and 
developing model. The entire dataset is divided into k subsets of roughly equal 
size. Each time, one subset is chosen as the validation set and the rest of 
subsets are used as training sets (See Figure 2-6 as an example of 5-fold CV). 
This process is repeated k times, resulting k-fold, and each subset is used 
exactly once for validation purposes.  
 
Figure 2- 6 Five-fold cross validation 
2.5 Model performance metrics 
Model performance is tested on validation set during running each fold of 
cross validation. After k-fold CV, k performance scores will be obtained. The 
average k performance score is called a CV score. The model with the best CV 
score, indicating the model with the best predicting ability, is selected as the final 
optimal model.  
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The Receiver Operating Characteristic (ROC) curve uses a graphical 
approach to display classifier performance at all classification threshold (see 
Figure 2-7). The true positive rate (TPR) and false positive rate (FPR) are plotted 
on the  y-axis and x-axis, respectively, and are defined as follows: 
𝑇𝑃𝑅 =  
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 (𝑇𝑃)
𝑇𝑃 + 𝐹𝑎𝑙𝑠𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 (𝐹𝑁) 
𝐹𝑃𝑅 =  
𝐹𝑎𝑙𝑠𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 (𝐹𝑃)
𝐹𝑃 + 𝑇𝑟𝑢𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 (𝑇𝑁) 
 
ROC = Receiver Operating Characteristic 
Figure 2- 7 ROC curve 
TPR measures sensitivity, the ability of a model to correctly classify the 
positive cases. In this project, it would be correctly classifying patients with AEs. 
It is the proportion of true positives that are correctly classified as positive. High 
sensitivity means that there are few false negative (FN) results, meaning that 
fewer positive cases are misclassified. 100% sensitivity indicates that the model 
correctly classified all positive cases. In this project, a high sensitivity was 
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required because positive cases are the targeted outcomes which are the 
patients who had AEs.  
Area under the ROC curve (AUC ROC) is another performance 
measurement used to evaluate the degree of misclassification and is generated 
as a summary statistic. AUC ROC ranges from 0 to 1 with a higher value 
indicating a better model ability to distinguish between classes. AUC ROC=0 
represents no data point is correctly classified by a model. AUC ROC=1 
represents model correctly classifies all data points.  
In this project, both sensitivity and AUC ROC were used as evaluation 
metrics. A combination of a high AUC ROC and high sensitivity were required 
when selecting the best model. If models have similar AUC ROC and sensitivity, 
then computational complexity will need to be considered. In this case, the most 
simple model with low computational complexity should be selected. 
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Chapter 3 Cohort extraction and preliminary studies 
This chapter elaborates the component 1 and component 2 (Figure 1-1) 
- data cohort extraction, raw data preprocessing, and adverse events risk 
evaluation in CVD patients who initiated statin agents for secondary 
prevention. 
3.1 Introduction 
The interest in big-data study is increasing recently. There is a need to 
extract value from the data to improve patient management and outcomes. To be 
successful with this work, the key initial challenge was the selection of an 
appropriate data cohort to support this project. This is especially important for a 
large-data study because a specific data cohort needs to be extracted from this 
large database for a specific research focus while also minimizing potential bias. 
Our original cohort was pulled from the OLDW - a database comprising more 
than 20 years of data representing more than 200 million de-identified lives, 
and containing hundreds of variables. Most of the lives in this database did not 
meet the inclusion criteria of our study and many of the original data elements 
could not be used directly for this study. In addition, when developing machine 
learning models, unrelated data elements can cause modeling complexity and 
negatively influence the ability to learn clear patterns from the data.  
This chapter demonstrates how an appropriate data cohort was extracted 
from the OLDW to optimally support this machine learning and DDIs research. 
The preliminary results of our patient cohort will also be discussed. 
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3.2 Methods 
A series of tasks were developed to extract an appropriate data cohort 







Note: OLDW = OptumLabs Data Warehouse 
Figure 3- 1 Summarization of data-extraction tasks to support the DDI and 
machine learning research activities. 
3.2.1 Target Clinical Group  
3.2.1.1. Chronological data inclusion 
The OLDW contains multi-year data back to year 1993. Selecting 
reasonable and manageable years of data is very crucial for study feasibility and 
generalizability. 2010 was selected as the start year to look for events based on 
the following reasons. a) Medicare Part D went into effect in 2006, affecting 
pharmaceutical coverage prices and the utilization of prescription medications 
with changes in coverage from other insurance plans to Medicare Part D. b) 
Seven statin agents (atorvastatin, lovastatin, fluvastatin, pravastatin, pitavastatin, 
simvastatin, and rosuvastatin) were included in this study. Pitavastatin, which is 















approval in 2009 and was brought to the market in 2010. Therefore, completed 
prescriptions of all available statins can be obtained starting in 2010. 
3.2.1.2. Inclusion and exclusion criteria 
Statin claims were selected based on the generic name which includes 
atorvastatin calcium, fluvastatin sodium, lovastatin, pitavastatin calcium, 
pravastatin sodium, rosuvastatin calcium, and simvastatin. To support the 
research purposes, the patient cohort was selected based on the following 
criteria:  
1) Only 40+ years old CVD patients were selected. The prevalence of 
CVD in patients aged 40 years and above increases substantially from 10% to 
40% compared with patients from 20 - 39 years old based on a national survey 
from 2009 to 201289. In addition, physical condition and adverse event patterns in 
younger group is different from the older group. Therefore, only patients who 
were 40-years-old or above and had a stroke, myocardial infarction, and/or 
coronary revascularization since year 2010 were included. Younger population 
may be considered added in our future study which include a broader population. 
Patients with radiation induced coronary artery disease (CAD) or heart transplant 
related CAD were excluded since the CAD mechanism and treatment strategies 
are different from other CVD.   
2) New CVD patients with no prior CVD history. Patients should not have 
any CVD diagnose within one year prior to the CVD index date. CVD index date 
was defined as the first CVD diagnosis date starting from 2010. CVD events 
were identified by a set of diagnosis and procedure codes (see Supplementary 
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Table 2) using both inpatient and outpatient codes. Those medical codes were 
selected by clinical expert review on a published paper 90 and Centers for 
Medicare and Medicaid Services (CMS) chronic conditions data warehouse 
(CCW) chronic condition reference list.  
3) New statin users who filled an index statin prescription within 30 days 
after the CVD index date. We required that patient had no statin prescription 
within one year prior to the statin index date to assure the cohort patients were 
newly initiated statins. Statin index date was defined as the first statin 
prescription date after CVD index date. Previous study also required no CVD 
claims and no statin prescriptions within one year prior to the index date in order 
to extract new statin and CVD patients91. 
4) All patients were followed up for up to one year after the statin index 
date to determine the patterns of statin use (continuous, discontinued, or drop 
out) and observe adverse events. Adverse events typically occur early in the 
therapeutic course of statin therapy 92,93. One-year follow-up is likely sufficient to 
capture most of the clinical events and made it easier to conduct comparisons in 
subsequent work. 
5) Statin index date had to be prior to 9/1/2014. Cohort extraction work 
was processed in early 2016. Medical claims in OLDW less than 6 months old 
can still be in the process of adjudication and have yet to be finalized. Therefore, 
I only used medical claims before September 2015 in order to get complete 
medical claims. Using this criteria, the statin index dates should be between 
1/1/2010 and 8/31/2014.  
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6) Patients were required to have continuous medical and pharmacy 
enrollment one year prior to the CVD index date and one year and one month 
after statin index date. The reason that an extra one month of continuous 
enrollment was needed after one-year follow-up is that I used 30-day window to 
differentiate pattern of statin use (details are described in ‘treatment plan and 
behavior’ section). Therefore, one extra month of statin claims was needed to 
categorize some patients.  
7) To reduce the bias due to treatment plan transition, only patients who 
maintained the same treatment plan were included (consistent statin agent and 
dosage; see Table 3-3). In other words, this patient group only had one treatment 
plan before statins were discontinued, an AE occurred, or the end of the one-
year follow-up period was attained.  
8) Patients who used combination drugs including amlodipine/atorvastatin, 
ezetimibe/atorvastatin, ezetimibe/simvastatin, niacin/simvastatin, 
sitagliptin/simvastatin, lovastatin/niacin, and aspirin/pravastatin were excluded. 
Specifically, combination drugs include two or more drugs in the same tablet, of 
which one is a statin agent. To keep the cohort patients more generalizable, 
those patients were excluded from this study because the combination 
medications may have different pharmacodynamics and patterns of use for 
patients receiving therapy. Because the statins are frequently given at different 
times than other medications, such as with dinner or before bed, having them 
combined with another medication simultaneously may be problematic. For 
instance, if a participant experiences a side effect due to the non-statin 
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component of a combination drug, it would change their medication experience, 
affect patterns of AEs, and potentially make predictive modeling more difficult 
and less generalizable for statin medications. Flowchart of study cohort selection 














Note:  OLDW = OptumLabs Data Warehouse  
CVD = cardiovascular disease 
CE = continuous medical and pharmacy enrollment 
Figure 3- 2 Flowchart for selection of the study population from OLDW 
1. CVD Patients (2010 to 
current) 
(N=2,595,087) 
2. Age >= 40-year-old  
(N=2,516,732,)  
3. CE: 1 year prior and 
after CVD index date 
(N=632,177) 
4. New CVD patients 
(N=521,862) 
6. New statin users 
(N=61,641) 
7. Statin index date before 
9/1/2014 (N=48,953) 
8. CE: 1 year before and 1 
year and 1 month after 
statin index date 
(N=47,700) 
9. Remove statin 
combination users and 
people who had multiple 
records on the same day 
(N=46,808) 
10. Patients without 
treatment plan transition 
(N=38,214) 
5. Statin users 
(N=195,164) 
Entire OLDW Claims 
patients (1993 to 2016) 
(Over 200 million) 
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3.2.2. Potential Predictors in predictive model 
The predictive model is intended to predict the risk of adverse events. 
Predictors (variables) that can be obtained from the OLDW were included. 
Specifically, these variables include demographic variables, type of insurance 
(commercial, Medicare Advantage), medical cost (both patient and health plan 
paid amounts), medication costs (both patient and health plan paid amounts), 
administrative claim comorbidities, provider specialty, and other variables that 
can be collected in the OLDW (See details in Supplementary Table 3). 
3.2.3. Treatment Plan and Behavior 
Previous studies have shown that the risk of AEs is associated with 
specific statin agents34,94,95 and a statin dose effect21,96,97. Statin were 
categorized into three intensity groups (low, moderate, and high intensity), based 
on the 2013 American College of Cardiology/American Heart Association 
(ACC/AHA) guideline on the treatment of blood cholesterol6 (see Table 3-1). In 
addition, patients’ statin tolerance behaviors were classified into three groups, 
continuous, discontinued, and dropout, to facilitate observation of the extracted 
data. People who continuously used statin treatment for at least one year without 
any gap longer than 30 days were categorized as continuous group. Patients 
who had only one statin prescription during the study period were categorized as 
dropout group. Patients in the discontinued group are those who had a gap more 
than 30 days or did not continuously use statin treatment for one full year. Gap 
was calculated as follows: 
Gap days=2nd statin fill date - (1st statin fill date + 1st fill of days of supply) 
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Table 3- 1 Statin intensity groups 
Statin 
Intensity 
Low Moderate High 
Atorvastatin -- 10mg, 20mg 40mg, 80mg 
Simvastatin 5mg, 10mg 20mg, 40mg 80mg 
Pravastatin 10mg, 20mg 40mg, 80mg -- 
Rosuvastatin -- 5mg, 10mg 20mg, 40mg 
Lovastatin 10mg, 20mg 40mg 60mg 
Pitavastatin 1mg 2mg, 4mg -- 
Fluvastatin 20mg, 40mg 80mg -- 
 
3.2.4. Outcome measurements 
The statin related AEs are the main outcomes in the drug-drug interaction 
study and the predicted outcome in the treatment plan predictive model. They 
were identified by International Classification of Diseases, 9th Revision, Clinical 
Modification (ICD-9-CM). In this project, only major clinically important AEs were 
considered including rhabdomyolysis, myopathies, renal events, liver events, and 
medication poisoning events associated with statins (See Table 3-2). Some 
minor AEs, such as muscle pain, were not considered, since they may not have 
consistent ICD-9 codes and likely only exist in clinical notes in many cases 
creating risk of misclassification.  
Incidence rates (IRs) of statin adverse events were used to evaluate the 
adverse event results. It was calculated as the number of incident cases divided 
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by the total person-time and was reported as the number of cases per 100 
person-years. Person-time was calculated as the time when patients were at risk 
of adverse events during the study period. Person-time was censored at the point 
that patient experienced an adverse event, stopped using statins, or reached the 
end of the observation time of the study, whichever happened first.  
Table 3- 2 Selected ICD-9 codes of adverse events 
Adverse events ICD-9 Codes 
Rhabdomyolysis 728.88 98 
Myopathies 359.4, 359.8, 359.9, 728.8, 728.89, 728.9, 
729.1, 791.3 24,99 
Acute kidney injury 584.XX 100,101 
Liver events 570, 573.X 102,103 
Poisoning events 972.2, E942.2, E980.4 24 
3.3 Results 
We had more than 2 million CVD patients who were 40-year-old or above 
in the OLDW (Figure 3-2). After imposing one-year continuous medical and 
pharmacy enrollment before and after the CVD index date, there were 632,177 
patients left. Then patients who had any CVD diagnosis or statin prescription 
within the 1-year drug and disease free period were removed and 61,641 new 
CVD and statin users were obtained. Then 12,688 patients whose statin index 
dates were after August 31, 2014 were excluded. After imposing continuous 
enrollment of one year before and one year and one month after statin index date, 
47,700 patients included. To keep the cohort simple and pure, 892 people were 
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excluded because of using statin combination therapy or having multiple statin 
prescriptions on the same day. Among the 46,808 patients, 8,594 patients either 
switched to another statin agent or modified the statin dose. In all, 38,214 
patients were included in the final cohort population who adhered to the same 
statin treatment plan within the observed time period. 16,333 (42.7%) patients 
had Medicare Advantage plans and the rest had commercial plans. Table 3-3 
shows the patient numbers for each number of statin treatment plans and 
number of patients who maintained the same statin agent but decreased or 
increased the statin strength. 
Table 3- 3 Summary of number of statin treatment plans change during the study 
period 
# Statin treatment 
plan changes 




statin agent, n 
0 38,214 (81.6) NA NA 
1 7,417 (15.8) 4,342 3,075 
2 1,022 (2.2) 273 749 
3 135 (0.3) <11 >124 


























Atorvastatin 15,440 (40.4) 63.5±11.6 64.2 NA 6,976 8,464 
Simvastatin >13,801 (36.1) 64.9±11.7 58.7 1,750 11,449 >602 
Pravastatin 5,210 (13.6) 65.5±11.6 55.2 2,314 2,896 NA 
Rosuvastatin 3,223 (8.4) 61.1±10.8 63.6 NA 1,980 1,243 
Lovastatin 433 (1.1) 66.3±11.7 53.8 311 122 0 
Pitavastatin 92 (0.2) 61.7±10.0 57.6 17 75 NA 
Fluvastatin <15 (<0.04) 57.9±9.2 * <11 <11 NA 
Note: * Due to the small size policy, percentage is masked. 
The mean age of the cohort population was 64.1 years (sd=11.7 years). 
The mean age for each statin agent group ranged from 57.9 years in fluvastatin 
group to 66.3 years in lovastatin group (Table 3-4). Atorvastatin was the most 
popular prescribed statin agent (40.4%), followed by simvastatin (36.1%). The 
gender distribution and the number of patients in each intensity group are also 
listed in Table 3-4. 
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Table 3- 5 The incidence rate for each adverse event by different statin agent groups 
Statins 
Incidence Rates (per 100 person-years) 
Any AEs Rhabdomyolysis Myopathy Renal Liver Poisoning 
Atorvastatin (n=15,540) 29.3 (28.1-30.5) 0.15 (0.07-0.23) 19.0 (18.1-19.9) 5.9 (5.4-6.4) 5.1 (4.6-5.5) 0.16 (0.08-0.25) 
Simvastatin (n>13,801) 30.0 (28.7-31.3) 0.26 (0.15-0.37) 20.4 (19.3-21.4) 6.0 (5.5-6.6) 4.4 (3.9-4.8) 0.05 (0-0.10) 
Pravastatin (n=5,210) 32.2 (30.0-34.5) 0.14 (0.00-0.28) 21.7 (19.9-23.6) 6.4 (5.5-7.4) 4.4 (3.6-5.2) 0.14 (0-0.28) 
Rosuvastatin (n=3,223) 25.3 (22.7-27.9) 0.25 (0.01-0.50) 17.5 (15.4-19.6) 3.8 (2.8-4.7) 4.0 (3.0-5.0) 0.06 (-0.06-0.19) 
Lovastatin (n=433) 23.9 (17.1-30.7) 0.46 (-0.44-1.36) 18.2 (12.4-24.1) 4.7 (1.8-7.5) 3.2 (0.8-5.6) 0 
Pitavastatin (n=92) 25.6 (7.9-43.3) 0 25.6 (7.9-43.3) 0 3.0 (-2.9-8.9) 0 
Fluvastatin (n<15) 0 0 0 0 0 0 
Note: AE = adverse event
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Table 3-5 summarizes the incidence rates for specific adverse event by 
different statin agent group. Each individual adverse event as well as the 
combination of all AEs were investigated. The IRs of combined adverse events 
ranged from 25.3 cases (rosuvastatin) to 32.2 cases (pravastatin) per 100 
person-years. For rhabdomyolysis, lovastatin users had the highest IR (0.46 
cases per 100 person-years). Pravastatin and atorvastatin users had similar IRs 
(0.14 and 0.15 cases per 100 person-years, respectively). Rosuvastatin and 
simvastatin also had very similar IRs (0.25 and 0.26 cases per 100 person-years, 
respectively). For myopathy, rosuvastatin group had the lowest IR (17.5 cases 
per 100 person-years), while pitavastatin had the highest IR (25.6 cases per 100 
person-years). For renal events, the incidence rates ranged from 3.8 cases 
(rosuvastatin) to 6.4 cases (pravastatin) per 100 person-years. For liver events, 
pitavastatin had the lowest IR (3.0 cases per 100 person-years) and atorvastatin 
had the highest IR (5.1 cases per 100 person-years). IRs of poisoning events 
were between 0.05 cases (simavastatin) to 0.16 cases (atorvastatin) per 100 
person-years. 
The entire cohort was then divided into three groups - continuous, 
discontinued, and dropout. Among the cohort patients, 39.4% maintained the 
same statin regimen for at least one year (continuous), 13.3% had only one statin 
prescription (dropout), and the remainder of patients discontinued statin 
treatment within one year (discontinued) (see Table 3-6). The duration of 
exposure to statins was also calculated during the study period. The average 
continuous statin exposure time for the continuous, discontinued and dropout 
	 43	
group were 11.8 months, 4.2 months, and 1.2 months, respectively. 
Comparisons were further conducted after stratifying by individual statin (Table 3-
7). Pitavastatin has the highest discontinuation and dropout rate. Rosuvastatin 
and lovastatin have moderate discontinuation and dropout rate. Atorvastatin, 
simvastatin and pravastatin have the lowest discontinuation and dropout rate. 












Continuous 39.4 65.0±11.4 64.3 14793.7 
Discontinued 47.3 63.4±11.7 60.2 6303.7 
Dropout 13.3 64.3±12.2 52.9 514.9 
 
Table 3- 7 Demographic characteristics for each tolerance group stratified by 














Atorvastatin Continuous 42.7 63.9±11.3 67.6 6,484.2 
 Discontinued 46.0 62.9±11.7 63.0 2,569.0 
 Dropout 11.3 64.6±12.5 56.6 173.3 
Simvastatin Continuous 38.9 66.2±11.4 62.0 5,276.0 
 Discontinued 46.8 64.0±11.8 58.3 2,273.9 
 Dropout 14.3 64.3±12.2 50.9 198.4 
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Pravastatin Continuous 36.9 67.4±11.3 56.9 1,890.2 
 Discontinued 47.0 64.4±11.6 56.3 817.0 
 Dropout 16.0 64.8±11.8 48.1 88.4 
Rosuvastatin Continuous 31.4 60.8±10.2 69.5 990.5 
 Discontinued 54.5 61.0±10.8 61.9 550.4 
 Dropout 14.1 62.5±12.1 57.0 44.4 
Lovastatin Continuous 31.2 68.8±10.7 53.3 133.1 
 Discontinued 53.6 65.5±12.2 54.3 77.0 
 
Dropout 15.2 64.1±11.0 53.0 8.0 
Pitavastatin Continuous 18.5 60.9±9.0 * 16.7 
 Discontinued 57.6 61.5±9.8 62.3 14.5 
 Dropout 23.9 62.9±11.3 * 2.0 
Fluvastatin Continuous * 52.7±11.5 * * 
 Discontinued * 61.6±10.0 * 1.9 
 Dropout * 57.0±3.6 * 0.4 
Note: * Due to the small size policy, percentages are masked. 
Table 3- 8 Incidence rates for each adverse event group stratified by statin 
tolerance group 















Continuous 2,695 12,950 20.8 (20.0-21.6) 
Discontinued 2,489 5,659 44.0 (42.3-45.7) 




Continuous >10 * 0.09 (0.04-0.14) 
Discontinued 22 6,300 0.35 (0.20-0.50) 
Dropout <11 * 1.6 (0.5-2.6) 
Myopathy 
(N=3,920) 
Continuous 1,793 13,535 13.2 (12.6-13.9) 
Discontinued 1,784 5,839 30.6 (29.1-32.0) 
Dropout 343 491 69.9 (62.5-77.3) 
Renal events 
(N=1,233) 
Continuous 597 14,411 4.1 (3.8-4.5) 
Discontinued 563 6,174 9.1 (8.4-9.9) 
Dropout 73 510 14.3 (11.0-17.6) 
Liver events 
(N=980) 
Continuous 526 14,481 3.6 (3.3-3.9) 
Discontinued 395 6,213 6.4 (5.7-7.0) 




Continuous * * 0.11 (0.06-0.16) 
Discontinued * * 0.06 (0.00-0.13) 
Dropout * * 0.78 (0.02-1.54) 
Note:  AEs = adverse events.  
          IRs = incidence rates. 
*: Due to the small size policy, numbers are masked. Some total person-
years are also masked because the number of patients can be back-calculated 
using IR and total person years. 
Table 3-7 summarizes the observation in terms of number of AE patients, 
total person-years, and the IRs. IR of continuous group was then used as the 
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reference group to calculate and compare the incidence rate ratio (IRR) (see 
Figure 3-3).  
 
Note: IRR = incidence rate ratio; CI = confidence interval 
Figure 3- 3 Incidence rate ratio for each adverse event group stratified by statin 
tolerance group as compared to continuous group 
For overall adverse events, the average person-years each patient 
contributed to the continuous, discontinued, and dropout groups were 0.98 
person-years, 0.35 person-years, and 0.1 person-years, respectively. The IRs of 
continuous, discontinued, and dropout group were 20.8, 44.0, and 94.5 cases per 
100 person-years (Table 3-7). The IRs of discontinued and dropout groups were 
significantly 2.11 times (95% CI, 2.00-2.23) and 4.54 times (95% CI, 4.11-5.01) 
greater than that of the continuous group (Figure 3-3). 
For rhabdomyolysis, myopathy, renal events, and liver events, the 
continuous group had the lowest IRs (0.09 cases, 13.2 cases, 4.1 cases, and 3.6 
cases per 100 person-years, respectively) and dropout group had the highest IRs 
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(1.6 cases, 69.9 cases, 14.3 cases, and 11.6 cases per 100 person-years, 
respectively). The IRs for both discontinued and dropout groups were 
significantly higher than that of in the continuous group. 
For poisoning events, the IRs ranged from 0.06 cases per 100 person-
years in the discontinued statin users group to 0.78 cases per 100 person-years 
in the dropout users group. The IR of the discontinued group was 0.59 times of 
the continuous group, but was not statistically different (95% CI [0.20 – 1.75]). 
The IR of the dropout group was significantly 7.18 times higher than that of in the 
continuous group (95% CI [2.4 – 21.5]). 
3.4 Discussion 
To improve the chance of success of the entire project, I extracted an 
appropriate patient cohort to investigate drug-drug interaction to facilitate 
development of prediction models.  
Preliminary tests were conducted to get a general idea about the 
characteristics of the cohort patients. 38,214 patients maintained the same statin 
treatment plan within one year and were selected as the final cohort. Among 
those patients, 40.4% of patients used atorvastatin, followed by simvastatin 
which is the second most prescribed statin representing 36.1% of the cohort 
patients. Nearly 40% of patients continuously used a statin for at least one year. 
The rest of the patients either discontinued the statin after a period of time or 
stopped the statin after their first statin prescription. This is consistent with 
previous studies10,27. The average time of statin therapy for patients in the 
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continuous, discontinued, and dropout groups were 11.8 months, 4.2 months, 
and 1.2 months, respectively. 
Individual AEs as well as the combination of all types of AEs were also 
investigated. Patients in discontinued and dropout groups generally had higher 
IRs than continuous group. AEs in these groups may contribute to patient’s 
decision to discontinue statins. When AEs were compared by each statin agent 
group, pravastatin was found to have the highest IRs for combination AEs and 
renal events. Pitavastatin users had the highest IR of myopathy. Atorvastatin 
users had the highest IRs of liver and poisoning events. Lovastatin users had the 
highest IR of rhabdomyolysis. Myopathy was the most common adverse event. 
Renal and liver events had much lower IRs. Rhabdomyolysis and the poisoning 
events were very rare. 
Limitations in this section of the study included: 1) Only patients without 
statin treatment transitions were selected to be in the patient cohort, which 
reduces generalizability. However, this step was necessary to reduce possible 
bias in AE prediction due to changes in treatment plan. 2) Some AEs, such as 
mild muscle pain cannot be fully captured since patients may not be seen in the 
clinic, emergency department for mild pain, or it may only be noted in physician 
notes . Thus, only AEs with ICD-9 codes were selected. 3) The defined follow-up 
period was one year. If the follow-up period was longer, more AEs may have 
been detected, and vice versa. AE patterns may be different with different 
lengths of follow-up. 4) Affordable Care Act (ACA), which was enacted in 2010, 
changed healthcare in many aspects, such as increasing insurance coverage, 
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changing insurance standards, and affecting insurance premiums and healthcare 
cost. This would suggest that 2010 might be an unstable year as a lot of patient 




Chapter 4 Simvastatin drug-drug interaction 
This chapter includes component 3 (Figure 1-1) - evaluation on the effect 
of the combination therapy of simvastatin and several pre-defined high risk 
interacting drugs (CYP3A4 and/or OATP inhibitors) in CVD patients using 
simvastatin medications for secondary prevention. 
4.1 Introduction 
Drug-drug interactions are a common cause of AEs which are responsible 
for up to 2.8% of hospital admissions1. Many CVD patients may need statins as 
well as other therapies, especially in those who have multiple comorbidities, and 
those at high CVD risk who cannot achieve optimal therapeutic benefits from 
statin monotherapy. 
In this chapter, I focused on simvastatin drug-drug interaction as 
simvastatin is one of the earliest statins that was approved by FDA and has a 
long history of medical application. It is one of the most commonly prescribed 
statin agents. According to our data, simvastatin (36.1%) and atorvastatin (40.4%) 
are the two most prescribed statin agents. They are both metabolized by the 
enzyme cytochrome P450 3A4 (CYP3A4). However, simvastatin undergoes 
more pre-systemic metabolism than atorvastatin104 which results in lower 
bioavailability for simvastatin (<=5%) compared with atorvastatin (12%). Drugs 
with high intestinal and liver extraction are often involved in significant DDIs when 
concomitant use with enzyme inhibitors or inducers. Therefore, simvastatin is 
more susceptible to medicine interactions. Study showed that simvastatin’s blood 
levels may be increased five-fold or higher by CYP3A4 inhibitors105. In addition, 
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FDA restricted the use of the highest approved dose of simvastatin (80mg) 
because of its increased risk of muscle related events106. FDA recommended 
that “simvastatin 80 mg should be used only in patients who have been taking 
this dose for 12 months or more without evidence of muscle injury (myopathy)”. 
Given the innate characteristics of simvastatin, its long history of use and large 
number of individuals using the medication, it is an important medication on 
which to assess the risk of adverse events associated with DDI exposures.  
The purpose of this chapter was to evaluate the effect of combination 
therapy of simvastatin and several pre-defined high risk interacting drugs, which 
are CYP3A4 and/or OATP inhibitors, on CVD patients in a large administrative 
claims dataset. Many case reports51,70,107,108 of DDI associated AEs involved 
concomitant use of simvastatin and CYP3A4 or OATP1B1 inhibitors. A few 
population-based studies50,109–111 investigated statin DDIs. However, they either 
focused on composite statin use or composite interacting drugs which cannot be 
used to determine the interactions induced by a specific statin and specific 
interacting drug. Our study extends these findings by focusing on one specific 
statin (simvastatin) and several predefined high risk interacting drugs. To better 
understand the interactions between simvastatin and specific  interacting drugs, 
three drugs which were known metabolic inhibitors were selected for subgroup 
analysis due to their relatively large sample size with adequate power for 
statistical analysis. In addition, to the best of our knowledge, no published 
population-based study specifically differentiated among different time periods: 
pre-DDI, DDI exposure, and post-DDI time periods. Comparisons between the 
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DDI-exposed group and non-DDI-exposed groups as well as the comparisons 
within subjects among those with DDI-exposure including pre-DDI, DDI exposure, 
and post-DDI time frames were performed. 
4.2 Methods 
4.2.1. Study population 
The patients for DDI study were selected from the cohort patients who 
were prescribed simvastatin. They were divided into two groups according to 
whether they were exposed to the predefined high risk interacting drugs: DDI 
group (exposed to an interacting drug) and non-DDI group (not exposed to an 
interacting drug). DDI group patients were identified when concomitant 
administration of at least one interacting drug during the simvastatin exposure 
period. The concomitant medication was defined as occurring when the 
prescriptions of simvastatin and the interacting drug had an overlapping 
exposure period.  
4.2.2. Interacting drugs 
The interacting drugs were selected by clinical expert review after carefully 
screening available DDI resources including drugs.com, Lexicomp, Epocrates, 
and published literature49. Drugs that had the highest DDI risk across each of the 
DDI resources were selected, including clarithromycin, telithromycin, 
erythromycin, nefazodone, itraconazole, ketoconazole, posaconazole, boceprevir, 
danazol, cobicistat, gemfibrozil, and cyclosporine. These medications are 
CYP3A4 and/or OATP inhibitors and had been previously identified as increasing 
risk of AEs with simvastatin.  
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To investigate the safety of specific interacting drugs, a subgroup analysis 
was conducted among three interacting drugs - gemfibrozil, clarithromycin, and 
erythromycin, as they had a relatively large number of patients with adequate 
power for statistical analysis. 
4.2.3. Study time frames definition 
For patients in the DDI group, the study period was divided into three time 
frames: 1) pre-DDI which was prior to initiation of DDI agent, 2) DDI exposed 
which was while the patient took simvastatin and an interacting medication 
without any gap longer than 30 days, and 3) post-DDI which was after the DDI 
exposure ended. AEs were detected during each of the above time periods. 
 
Note: DDI = drug-drug interaction 
Figure 4- 1 Scenarios of statin-drug interaction and illustration of pre-DDI and 
post-DDI period for each scenario 
4.2.4. Outcome measures 
Major clinically important AEs that were discussed in Chapter 3, including 
rhabdomyolysis, myopathies, renal adverse events, hepatic adverse events, and 
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statin poisoning events, were included. 
Incidence rates were used to evaluate the risk of AEs in different groups 
by accounting for the potential difference of length of drug exposure. IRs were 
reported as the number of cases per 10 person-years of exposure.  
The number of physician claims per month was used as another study 
outcome to assess if patients with DDI exposure had increased clinical follow-up 
to manage the potential DDI risk compared with non-DDI group. This study 
hypothesized that subjects exposed to the interacting drugs would have more 
intense medical follow-up. Physician claims on the same day were counted as 
one claim. Outpatient claims, emergency room (ER) visits, and office visits were 
included in the physician claim totals.  
In addition, Charlson comorbidity index score was compared between 
groups. The Charlson comorbidity index is the most widely used for predicting 
one-year mortality based on comorbidity data 112. It has also been used as a 
predictor for adverse events113–120. The index score was used instead of single 
comorbidities because it is a summary comorbidity measure reflecting risk of 
death from many comorbid diseases. A score of zero indicates that no 
comorbidities were found. The higher the score, the more likely that death will 
occur.  
4.2.5. Statistical analysis 
R software was used for analysis. Two-tailed t-students tests were 
performed for continuous variables. 95% confidence intervals (CI) were 
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calculated for incidence rate ratio. Analyses were carried out with RStudio 
version 0.98.1103. A p-value < 0.05 was considered statistically significant. 
4.3 Results 
13,801 simvastatin CVD patients, who did not have any interacting drug or 
had only one interacting drug, were included in this study. Patients who took two 
or more different interacting drugs during simvastatin exposure time period were 
excluded because they had a complex pre-DDI and post-DDI period and a very 
small sample size (N<11).  
To protect patient privacy and confidentiality, small numbers or small 
percentages which represent small numbers (N<11) cannot be reported 
according to the OptumLabs cell size suppression policy.  
 
Note: DDI = drug-drug interaction 
Figure 4- 2 Patient number for non-DDI group, DDI group, and sub-DDI groups 
A total of 264 patients were identified in the DDI group including 112 
clarithromycin patients, 106 gemfibrozil patients, 32 erythromycin patients, and a 
total of 14 patients who took ketoconazole, nefazodone, cyclosporine, or 
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itraconazole. No patient used telithromycin, posaconazole, boceprevir, danazol, 
or cobicistat. Figure 4-2 shows the patient number in each group and sub-group. 
4.3.1 Baseline comparison between DDI group and non-DDI group 
A comparison of baseline patient characteristics between simvastatin DDI 
group and non-DDI group is shown in  . From the table, we can see DDI group 
had a significantly longer statin exposure time and higher Charlson score than 
non-DDI group. Table 4-2 shows IRs comparison between DDI and non-DDI 
group. DDI group had a 1.29 times higher incidence risk of AEs compared with 
the non-DDI group after adjusting for statin exposure time. (See Supplementary 
Figure 1 for key dates, time period and outcomes illustration.) 
Table 4- 1 Patient characteristics comparison between DDI and non-DDI groups 





Statin exposure time (days) 249.1 204.0 <0.0001* 
Age (years) 63.9 64.9 0.1555 
Male (%) 162 (61.4%) 7,934 (58.6%) 0.3646 
Charlson index score 1.55 1.10 0.0002* 
Intensity (%)    
        Low  30 (11.4%) 1,719 (12.7%) 0.5003 
        Medium 220 (83.3%) 11,226 (82.9%) 0.8616 
        High 14 (5.3%) 592 (4.4%) 0.505 
Note:  DDI = drug-drug interaction 
* indicates results are significantly different. 
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Table 4- 2 Incidence rate ratio comparison between DDI and Non-DDI groups 
 AE counts c IR a IRR b [95% CI] 
Non-DDI group (N=13,537) 1,957 2.84 --- 
DDI group (N=264) 13 3.66 1.29 [0.75, 2.22] 
Note: DDI = drug-drug interaction 
a. IR = incidence rate. 
b. IRR = incidence rate ratio. 
c. In DDI group, AEs were counted when they occurred during DDI 
exposure period. In Non-DDI group, AEs were counted when they 
occurred during the statin exposure study period. 
 
4.3.2 Physician claims comparisons 
Table 4-3 shows the results of the numbers of physician claims per month. 
Patients who did not have any physician claims were counted as contributing 
zero visits. Among the patient cohort, 642 patients (4.7%) resulted zero visits. 
Since only a small percentage of the cohort had zero visits, they were included in 
the following analysis.  
The results show that the DDI group had a significantly higher number of 
physician claims than the non-DDI group (2.53 claims/month vs. 2.17 
claims/month with p=0.0060). Similar analyses were done among the DDI group 
patients. 38 of 264 patients exposed an interacting drug throughout the whole 
simvastatin period (scenario 1 in Figure 4-1) resulting in zero days of DDI 
unexposed time for these patients. The number of physician claims per month 
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during the DDI exposed and unexposed time periods were 3.95 and 2.38 with a 
statistically significant p-value less than 0.0001. A significant result was also 
found when comparing the two DDI unexposed time periods. Pre-DDI period had 
a higher number of physician claims (3.22 claims per month) compared with the 
post-DDI period (1.91 claims per month). 
Table 4- 3 Physician claims comparisons between different groups 
Patients Groups Claim numbers per month  (N) p-value 
All patients DDI group 2.53 (N=264) 
0.0060* 
 Non-DDI group 2.17 (N=13,537) 
DDI patients DDI exposed period 3.95 (N=264) 
<0.0001*  DDI unexposed 
period** 
2.38 (N=226) 
DDI patients Pre-DDI 3.22 (N=164) 
<0.0001* 
 Post-DDI 1.91 (N=196) 
Note:  DDI = drug-drug interaction 
* Results are significantly different. 
** DDI unexposed period includes both pre-DDI and post DDI periods. 
4.3.3 Baseline comorbidities comparisons 
The above IRR and physician claim comparison did not adjust for 
comorbidities, thus we compared individual Charlson comorbidity between DDI 
and non-DDI group to get a better sense whether the differences may be able to 
explained by underlying comorbidity or are more likely to be explained by DDI. 
Table 4-4 shows DDI group has significantly higher percentage of patients with 
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pulmonary disease, rheumatologic disease, and diabetes (mild to moderate). 
However, liver and renal disease, which could potentially affect the AEs during 
medication exposure, does not show statistically significance.  
Table 4- 4 Incidence rate ratio comparison between DDI and Non-DDI groups 






Myocardial infarction <4.2% 3.7% NS1 
Renal disease 4.9% 4.9% 0.9974 
Moderate or severe liver disease <4.2% 0.14% NS1 
Mild liver disease 4.9% 3.1% 0.1657 
Congestive heart failure 5.7% 6.4% 0.6240 
Peripheral vascular disease 11.7% 8.1% 0.0687 
Cerebrovascular disease 8.3% 7.8% 0.7441 
Dementia <4.2% 0.92% NS1 
Chronic pulmonary disease 23.5% 16.1% 0.0052* 
Rheumatologic disease 9.1% 2.8% 0.0005* 
Peptic ulcer disease <4.2% 0.85% NS1 
Diabetes (mild to moderate) 31.4% 18.9% <0.0001* 
Diabetes with chronic 
complications 
6.8% 4.4% 0.1296 
Paraplegia or hemiplegia <4.2% 0.48% NS1 
Any malignancy, including 9.1% 7.8% 0.4839 
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lymphoma and leukemia 
Metastatic solid tumor <4.2% 0.73% NS1 
AIDS <4.2% 0.15% NS1 
Note: 1: NS: not significant. Small numbers or small percentages which represent 
small numbers (N<11) cannot be reported according to the OptumLabs cell size 
suppression policy. The corresponding P-values are replaced by NS if p-value is 
>0.05. 
4.3.4 Relationship between DDI exposure time and adverse event rates 
The estimated percentages of patients who had any type of AEs during 
DDI exposure period are shown in Figure 4-3. Individual patients contribute only 
1 AE if AE(s) occurred. A temporal association of percentage of AE patients with 
DDI exposure time was assessed. DDI group patients were divided into six 
groups based on the length of DDI exposure time (1-7 days, 8-15 days, 16-30 
days, 31-90 days, 91-270 days, and 271-365 days) to provide a general time 
frame for the occurrence of AEs. This figure indicates the number of people who 
have AE increases as the DDI exposure time increases.  
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Note:  AEs = adverse events 
 DDI = drug-drug interaction 
Figure 4- 3 Estimated percentage of AE patients with DDI exposure time 
4.3.4 Subgroup analysis in three specific interacting drugs 
Table 4-5 shows the results of the three specific interacting drugs: 
gemfibrozil, clarithromycin, and erythromycin. IRs were measured in pre-DDI, 
DDI exposure, and post-DDI time periods. Person time was calculated as the 
total time from the start date to the date of index AE occurrence or to the end of 
time period, whichever occurred first. IRRs were calculated using IR of non-DDI 
group (2.84 per 10 person-year) as the reference group. Both clarithromycin and 
erythromycin have higher IRs in all three time frames compared with non-DDI 
group. Gemfibrozil DDI group had significantly higher IR in the pre-DDI and DDI 
exposure period, but lower IRs in the post-DDI period (not significant) compared 
with the non-DDI group. The risks of AEs for clarithromycin and erythromycin 
were higher than gemfibrozil during DDI exposure and post-DDI time period. 
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However, gemfibrozil had the highest pre-DDI IR compared with the other two 
inhibitors. The highest IRs of clarithromycin and erythromycin occurred in the DDI 
exposed period. However, the highest IR of gemfibrozil occurred in the pre-DDI 
time period. 
Table 4- 5 Risk estimate in concomitant use of simvastatin and interacting drugs 
Interacting drugs (N) Time frames IRs IRRs** [95% CI] 
Gemfibrozil (N=106) Pre DDI 8.84 3.11 [1.17, 8.30]* 
DDI exposure 3.11 1.10 [0.57, 2.11] 
Post DDI 1.51 0.53 [0.23, 1.63] 
Clarithromycin (N=112) Pre DDI 3.26 1.15 [0.65, 2.02] 
DDI exposure 6.09 2.14 [0.54, 8.58] 
Post DDI 3.64 1.28 [0.74, 2.21] 
Erythromycin (N=32) Pre DDI 4.69 1.65 [0.69, 3.97] 
DDI exposure 16.04 5.65 [1.41, 22.60]* 
Post DDI 3.48 1.23 [0.46, 3.27] 
Note:  IR = incidence rate 
IRR = incidence rate ratio 
* Results are significantly different. 
** IRRs were calculated to compare with the non-DDI group IR which is   
2.84 per 10 person-year 
4.4 Discussion  
The drug interactions between statins and CYP3A4 and/or OATP1B1 
inhibitors are well recognized. However, studies that focus on the interactions 
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between simvastatin and specific interacting drugs are very limited. We pre-
selected several high-risk drugs that inhibited either CYP3A4 and/or OATP1B1 
and conducted a population-based study using administrative claims data to 
explore the actual exposures and risks of adverse events in CVD patients who 
were prescribed combination therapy of simvastatin and these pre-specified high 
risk interacting drugs. Given the well-described risk associated with these DDI 
exposures, it was expected that there would be very few individuals using these 
medication combinations. It was also expected that if these combinations were 
prescribed that there would be a need for greater clinical follow-up to monitor for 
potential adverse drug events related to DDI exposure. A subgroup analysis was 
also performed to investigate the interactions between simvastatin and three 
specific interacting drugs that few previous studies had evaluated and had 
substantial numbers of DDI-exposures in the study cohort. The study used real 
world data to provide empirical data on the actual risk of DDI exposure, the 
length of exposure, and the risk of clinically significant AEs. 
The baseline Charlson index score and simvastatin exposure time in the 
DDI group were significantly higher than the non-DDI group indicating the DDI 
group was a sicker population with longer simvastatin exposure time. DDI group 
had more medical follow-up than non-DDI group with a statistically significant 
result. The AE incidence rate in the DDI group is higher than the non-DDI group 
but was not statistical significant. Although results are not adjusted for Charlson 
comorbidity score, we compared the individual comorbidity between DDI and 
non-DDI group. We found baseline liver and renal disease, which could 
	 64	
potentially affect the AEs during medication exposure, are not statistically 
different. This may indicate the differences between the two groups are more 
likely to be explained by DDI. However, the increased comorbidities among those 
with DDI exposures may also contribute to a greater risk of illness including 
adverse drug events. 
Within the DDI group, the number of physician claims during the DDI 
exposed time period was more than that during the DDI unexposed time period. 
This indicates patients were receiving more medical care during the concomitant 
administration of simvastatin and interacting medications, potentially providing 
important clinical monitoring or physician visits for AEs. When comparing the pre-
DDI and post-DDI time periods, the results showed patients generally had more 
physician claims in pre-DDI than post-DDI time period. This may be due to 
patients having more intense physician follow-up in the months after the index 
CVD event to provide needed medication adjustments and control of 
cardiovascular risk factors. This study also showed that the number of patients 
with AEs increased with DDI exposure time which indicates longer DDI exposure 
may induce higher risk of AEs.  
When comparing the three inhibitors, we found clarithromycin and 
erythromycin had higher risk of AEs than gemfibrozil during DDI therapy. This 
may be because both clarithromycin and erythromycin are potent inhibitors of 
CYP3A4 and OATP1B1121–123, leading to a greater  total effect on the simvastatin 
by influencing two clinically important drug pathways. Gemfibrozil, on the other 
hand, is primarily dependent on OATP inhibition but not CYP3A4 leading to a 
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weaker overall inhibition. An interesting finding about gemfibrozil was that it had 
the highest IR of AEs during pre-DDI time period compared with the other two 
inhibitors. So we conducted a further investigation and found gemfibrozil group 
had substantially higher percentage of male patients (72.6%) compared with 
clarithromycin (55.4%) and erythromycin (46.9%) groups, which indicated the 
differences may be due to gender differences reflecting potentially different 
hormonal influences and associated pharmacogenomics. Likewise, the statin 
dropout rate in gemfibrozil patients was the highest (17%) among all three 
inhibitors. However, we do not have a solid reason to explain why gemfibrozil has 
a significant higher Pre-DDI IR. Further studies need to be conducted to see if 
similar result occurs. 
Our findings are consistent with a population-based cohort study50 which 
was conducted in Canada showing that the co-prescription of a statin 
metabolized by CYP3A4 with clarithromycin or erythromycin was associated a 
higher risk of hospitalization with rhabdomyolysis, acute kidney injury, and all-
cause mortality compared with azithromycin. Their outcomes were based on a 
composite of atorvastatin, simvastatin, and lovastatin and a composite of 
clarithromycin and erythromycin. Kellick et al.121 pointed out that gemfibrozil had 
a less profound effect on the statin medications. In contrast, Mesgarpour et al.109 
found the risk for hospitalization or death in persons receiving clarithromycin is 
not causally associated with the interactions between statins (atorvastatin, 
simvastatin, or lovastatin) and clarithromycin. Another cohort study110 focused on 
the concomitant use of statins and fibrates indicating that the combination 
	 66	
therapy of simvastatin and gemfibrozil increased the incidence of rhabdomyolysis 
hospitalizations. 
This study had several limitations. Patients may have been misclassified if 
1) AEs were not simvastatin-related AEs or induced by other drug interacting 
factors such as food (grapefruit juice124–126) or underlying clinical diseases (liver 
disease and renal dysfunction). However, the baseline comparisons showed no 
significant difference between the DDI and non-DDI group; 2) the initial AEs 
happened before starting interacting drugs and the follow-up visits that occurred 
after initiating interacting drugs were identified as adverse events due to timing 
accuracy problems; 3) events were not captured by the medical codes. There 
may be selection bias since the study population only included subjects with a 
stable statin dosage, however, it is not clear if this is likely to affect the 
occurrence of AEs in either the DDI or non-DDI exposed groups, but may affect 
generalizability of the findings. In addition, IR and physician claim comparison 
between DDI and non-DDI group were not adjusted for comorbidities. However, 
we compared individual comorbidities between two groups. Other limitations 
include the results that were based on the small size group, e.g. erythromycin, 
were difficult to draw meaningful conclusions, and the associations based on 
observational study may not be causal.  
4.5 Conclusions 
The potential statin-drug interactions in CVD patients are common and 
should be monitored to limit patient adverse events. The risk of adverse events is 
amplified when concomitant administration of simvastatin with clarithromycin or 
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erythromycin, which is likely due to the double paths to create drug interactions. 
The combination of simvastatin and gemfibrozil yield fewer adverse events than 
the combination with clarithromycin or erythromycin which may be due to single 
pathway inhibition. If possible, these inhibitors, especially clarithromycin and 
erythromycin, should be avoided in clinical settings when patients take 
simvastatin due to the risk of adverse events. 
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Chapter 5 Prediction for statin-associated adverse events 
using machine learning technologies 
This chapter shows how the component 4 in Figure 1-1 was implemented. 
Five classic machine learning models were developed to predict one-year risk of 
AEs among CVD patients after statin initiation.  
5.1 Introduction 
Machine learning (ML) methods, which are primarily used for prediction 
and exploratory studies, were used in this project for individualized prediction and 
data-driven decision making. ML approaches have been increasingly used in 
healthcare research for prediction because they are preferable to handle the size 
and complexity of health data and can provide powerful approaches to discover 
hidden patterns from large datasets. In recent years, the power of ML in 
diagnosing disease and in predicting treatment outcome empowers physicians 
and reduces time for decision making in the clinic. Instead of relying on reactive 
strategies, ML predictive modeling and Big Data approaches were used to 
develop proactive strategies. ML is intended to support provider decision making 
to prescribe a personalized statin treatment plan (both statin agent and dosage) 
based on multiple patient characteristics and concomitant drug therapy to 
minimize the individual’s risk of AEs. In developing a proactive strategy, ML 
algorithms are used to identify similar patients and their treatment plans in the 
data, generalize the treatment plan, and predict the personalized treatment plan 
that minimizes AEs risk to support prescription decisions. In this chapter, I will 
introduce how classic ML models were developed and how the optimal model 
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was selected to predict up to one-year risk of AEs among CVD patients after 
statin initiation. The performance comparison was also investigated among 
different feature sets including single feature, features selected by forward 
selection, clinical expert selected features, and all available features. In the future, 
this optimal predictive model could be integrated into a clinical decision support 











Figure 5- 1 Steps for model development 
Figure 5-1 shows all the steps that were implemented to develop machine 
learning algorithms and select the final optimal model. These include 1) data 
preprocessing; 2) random separation: divide the cohort patients into training 
sample and test set; 3) cross validation: validation technique used to train 




















the test set. Matlab version R2016b was used as the software to perform the ML 
tasks. 
5.2.1 Data preprocessing 
Variables that were skewed and had a wide distributional range were log 
transformed to obtain a normal distribution127. In addition, some continuous 
variables that were measured in different scales were not directly comparable 
and thus did not contribute equally to prediction. For instance, medical costs can 
range across multiple orders of magnitude causing cost data to have more 
weight than smaller value variables such as statin dosage. To reduce the chance 
that these variables dominate the model, feature scaling was used to rescale all 
continuous values into the range [0,1]. The formula is shown below, where X is 
the original value; X!"# and X!"# are the minimum and the maximum value of X. 





The cohort was divided into two datasets: the training sample and test set. 
The original dataset was randomly divided into six equal size subsets. One of the 
subsets was randomly selected as the test set, which was used to evaluate 
whether the final optimal model can make a reliable prediction on unseen data. 
Among the remainder of five subsets (training sample), only 14.7% patients were 
positive cases (patients who had any type of AEs, minority class) causing an 
imbalanced dataset. Models built on class-imbalanced data are often biased 
towards the majority class and cannot accurately predict the minority class. To 
balance the data, I randomly downsampled the majority class (patients who did 
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not have any AEs) to obtain an equal size of the majority class and the minority 
class (see Figure 5-2). In addition, the downsampling process was repeated 
three times with replacement to reduce the selection bias.  
 
Note:  Positive cases were patients who had adverse events.  
Negative cases were patients who did not have any adverse events. 
CV = cross validation. 
Figure 5- 2 Process of downsampling 
5.2.2 Predictive models development 
Five classic ML methods were initially investigated, including generalized 
linear model (GLM), support vector machine (SVM), decision tree, random forest, 
and artificial neural network (ANN). Final model selection was based on model 
performance and model complexity. 
GLM models including linear, interactions, pure quadratic, and quadratic 
functions were investigated. For SVM, kernel function is one of the 
hyperparameters that need to be tuned. Three kernel functions, including linear 
kernel, RBF kernel, and polynomial kernel, were tested. Three polynomial kernel 
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orders (2, 3, and 4) were also tested. Another hyperparameter is called box 
constraint (BC), which is a cost/penalty to the misclassification to adjust the 
boundary and the number of support vectors. When the data is not perfectly 
separable, the training algorithm must allow some misclassification in the training 
set. In this case, it is applying a cost to the misclassification. The higher the box 
constraint, the higher the cost of the misclassified points leading to a more strict 
separation of the data and more conservative classification. Seven BC numbers 
were tested: 0.001, 0.01, 0.1, 1, 10, 100, and 1000, which covered a wide range. 
Gini and entropy split metrics were investigated when developing the decision 
tree model128. Ten numbers (21, 22, 23, continuing all the way to 210) were chosen 
for both the maximal number of splits and the minimum number of leaf node 
observations. For random forest, two hyperparameters, including tree number 
(the maximum number of trees to build) and feature number (the number of 
features a random forest selects when splitting a node), were tuned. Tree 
number was tested from 1 to 500. The default value of feature number is 
𝑙𝑜𝑔!(𝑀 + 1), where M is the total number of features 129. However, when many of 
the variables are categorical, the number of features must be increased to about 
2 to 3 times of the default value in order to get enough strength to provide good 
accuracy on test set129. Since a total of 35 features were included, the default 
NumFeature is 5.2. In addition, many of the predictors are categorical, thus the 
number of features need to be increase to 10-16. Therefore, seven feature 
numbers were tested including 5, 7, 9, 11, 13, 15 and 17. For the neural network 
classification, three common training functions including Levenberg-Marquardt 
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optimization (LM), scaled conjugate gradient (SCG), and Bayesian regularization 
(BR) were tested. Previous studies130,131 showed that 1 or 2 hidden layers should 
solve most of the problems. Therefore, we tested hidden layer size from 1 to 5. 
A 5-fold cross validation was performed during model development. AUC 
ROC was used as the primary evaluation metric. In addition, sensitivity was also 
an important factor to measure model performance, because we did not want to 
misclassify the true positive cases. Computational complexity was also considered 
when models had similar AUC ROC and sensitivity. A simple model with low 
computational complexity was better than a complex model, because simple model is 
quicker to build, easier to implement, and easier to interpret than complex model. 
5.2.3 Outcome 
A combination of all types of AEs (myopathy, rhabdomyolysis, renal 
damage, liver damage, and statin poisoning events) was used as the predicted 
outcome. Positive cases who had any kinds of AEs were coded as ‘AE=1’. 
5.3 Results 
38,214 patients were included in our cohort population. 6,369 patients 
were randomly selected as the test set. Three downsampled training datasets 
were created from the original training dataset. Each training set contained 9,370 
patients which included 4,685 positive cases who had at least one type of AEs 
and 4,685 negative cases sampled from patients who did not have any type of 
AEs.  
5.3.1 Performance of different feature sets  
The original feature set included 74 features including age, gender, 
comorbidities, medical cost, statin cost, and other variables (See details in 
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Supplementary Table 3). Two comorbidity scoring methods, Charlson and 
Elixhauser comorbidities, are included in the original feature set. Only one of the 
comorbidity scores will be selected as a feature based on their predictive 
performances. Individual comorbidities were also selected by automated forward 
feature selection. 
GLM was used to evaluate and compare the prediction ability among four 
feature sets: single feature, 35 features selected by GLM forward selection 
(Supplementary Table 5), 32 domain expert selected features (Supplementary 
Table 5), and 74 all features (Supplementary Table 3). These comparisons 
showed: 1) how much improvement when using more features compared with 
the single feature; 2) the differences between machine selected features and 
clinical expert selected features based on domain knowledge. Table 5-1 shows 
the comparisons among three feature sets. The first column lists the top 10 
single features with the highest AUC ROC (see details in Supplementary Table 4 
for all the ordered single features). Each feature was used as the only one 
predictor in GLM and evaluated separately. AUC ROC was used to evaluate 
model performance and rank features. The second column lists the top 10 
predictors selected by GLM forward selection (see details in Supplementary 
Table 5). The last column shows whether these features were considered by a 
domain expert. This table shows that the features selected by GLM forward 
selection were clinically meaningful since they are highly consistent with what the 
clinical expert selected.  












Age X X X 
Gender X X X 
Charlson comorbidity score X X X 
Statin strength X X X 
Statin initiation gap1 X X X 
Statin exposure time X X X 
Health plan type2 X X X 
Statin cost (out-of-pocket)3 X  X 
Initial 30-day medical cost X X X 
Prescriber specialty  X X 
Elixhauser comorbidity score X   
Fluid and electrolyte disorders  X X 
Note: 1. Statin initiation gap is defined as the gap between CVD index date and 
statin initiation date.  
2. Health plan type includes commercial and Medicare Advantage. 
3. Cost was calculated as cost per 30 days. 
Figure 5-3 shows the performance comparison among different feature 
sets. The top three single predictors with best performance were included for 
illustration purposes. When compared with other feature sets, the results 
indicated that a single predictor did not have enough prediction power. Adding 
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more features improved the performance. Features selected by GLM forward 
selection had the highest AUC ROC and sensitivity. Clinical expert selected 
features had similar performance with GLM selected features. All features had 
relatively low performance compared with the other feature sets which indicates it 
may included some irrelevant features. The 35 features selected by GLM forward 
selection were used in the subsequent models (Supplementary Table 5).  
 
Figure 5- 3 Performances comparison among different feature sets 
5.3.2 Baseline characteristics comparison between randomized 
downsampling datasets 
The three downsampling datasets were randomly selected. Baseline 
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performed to verify if the random process was successfully conducted. Table 5-2 
shows that the patient baseline characteristics among the three groups are very 
similar. The randomized process was completed successfully. 
Table 5- 2 Baseline characteristics comparison among the three downsampling 
groups. 







Statin exposure time (days) 221.3 220.5 222.8 0.528 
Age (years) 65.5 65.5 65.4 0.965 
Male (%) 57.0 56.3 56.9 0.577 
Charlson index score 1.27 1.28 1.28 0.933 
 
5.3.3 Models development and comparison 
Model performance will be considered to be good if AUC ROC is greater 
than 0.80, moderate if values are between 0.60 and 0.80, and poor if values are 
less than 0.60. 
For GLM model, four models were included (see Table 5-3). The model 
performances are shown in Figure 5-4. Model 1 (linear model) had the highest 
AUC ROC. Its sensitivity is a little bit lower than the pure quadratic model, 
however, it is the simplest model among all models. Thus, the GLM linear model 
was identified as the best GLM model. 
Table 5- 3 GLM Models 
Model Model specific Distribution 
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Model 1 Linear Binomial 
Model 2 Interaction Binomial 
Model 3 Pure quadratic Binomial 
Model 4 Quadratic Binomial 
 
Figure 5- 4 Performances comparison of 4 different GLM models  
Thirty-five SVM models were built and compared. AUC ROC and sensitivity 
comparisons are shown in Figure 5-5 and Figure 5-6. AUC ROC and sensitivity 
generally increased as the box constraint increased, and then stopped increasing 
or decreased after a specific box-constraint value. Although the model with the 
radial basis function kernel and box constraint = 0.01 had the highest sensitivity, 
it had relatively low AUC ROC. Thus, we selected the linear kernel with box 



























Note:  bc = box constraint 
 rbf = radial basis function 
          poly kernel = polynomial kernel 
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 rbf = radial basis function 
          poly kernel = polynomial kernel 
Figure 5- 6 Sensitivity of different SVM models 
The random forest classifier was applied using classification method. The 
tree number was determined using out-of-bag (OOB) classification error132 which 
is an error estimation technique often used to evaluate the accuracy of a random 
forest and determine the optimal number of trees. Lower number of trees results 
less complex model. Figure 5-7 shows the OOB error decreased as the tree 
number increased. The OOB error tended to be stable after it reached a certain 
number. As a result, 250 trees were selected as the maximum tree number 
because the out-of-bag classification error was relatively stable after reaching 
250. To select the optimal features to split a node, 7 numbers were tested which 
are shown in Figure 5-8. We selected 13 as the optimal feature number because 
it had the highest AUC ROC and sensitivity.    
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Figure 5- 7 Out-of-bag error relationship to tree number 
 
Figure 5- 8 Performances of random forest 
For decision tree analysis, two split metrics were tested: Gini impurity and 
entropy. As discussed in 5.2.2, ten numbers (21, 22, 23, continuing all the way to 
210) were chosen for both the maximal number of splits and the minimum number 
of leaf node observations. Thus, for each split metric, 100 models were tested. 
The AUC ROC and sensitivity comparisons for the two split metrics are shown in 
Figure 5-9, Figure 5-10, Figure 5-11, and Figure 5-12. The x-axis represents the 
minimum number of leaf node observations (2!! ) and the y-axis represents 
performance score (AUC ROC or sensitivity). The legend represents the maximal 
number of splits (2!!). The performances of Gini impurity and entropy were very 
similar. Gini split metric was selected instead of entropy because entropy 
requires computation of logarithmic functions, which is more computationally 
intensive than Gini impurity. Gini model with maximum number of split = 512 and 
minimum number of leaf node observation =128 was chosen after considering 
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Figure 5- 9 AUC ROC of different decision tree models (Gini) 
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Figure 5- 11 AUC ROC of different decision tree models (Entropy) 
 
Figure 5- 12 Sensitivity of different decision tree models (Entropy) 
For the ANN classifier, five hidden layer sizes (from 1 to 5) and three 
network training functions were tested, resulting in a total of 15 models. 
Performance comparisons are shown in Figure 5-13. Levenberg-Marquard 
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because it had the highest AUC ROC. Although its sensitivity was a little bit lower 
than the Bayesian regularization training function with hidden layer size=5, the 
latter model is more complicated.  
To select the final optimal model, I compared the performance of the 
following classifiers: 1) GLM: linear model with binomial distribution; 2) SVM: 
linear kernel with box constraint=0.1; 3) random forest: maximum 250 trees and 
13 candidate predictors randomly drawn for a split; 4) decision tree: Gini model 
with maximum number of split = 512 and minimum number of leaf node 
observation =128; and 5) ANN: Levenberg-Marquard training function with 
hidden layer size=1. Figure 5-14 shows that GLM, SVM and ANN had relatively 
higher AUC ROC than the other two classifiers. However, GLM model was 
selected as the final optimal model as it has the highest sensitivity and is the 
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Figure 5- 13 (a) AUC ROC and (b) sensitivity of different artificial neural network  
Note:  BR = Bayesian regularization 
LM = Levenberg-Marquard 
SCG = scaled conjugate gradient 
Finally, the GLM model was validated on the test data, which was never 
used when built models, to assess model generalizability. The AUC ROC of the 
test dataset was 0.70.   
 
Note:  GLM = generalized linear model 
SVM = support vector machine 


















Hidder Layer Size 



























Figure 5- 14 Performances of different classification methods 
5.4 Discussion 
In this chapter, a machine learning model was developed using OLDW 
claims data to predict the one-year risk of adverse events after prescribing a 
statin treatment plan. This predictive model could potentially improve the 
adherence of statins and reduce the risk of statin-associated AEs. It can also be 
used in a future clinical decision support system by automatically comparing AE 
risks among different statin treatment plans and selecting the best statin 
treatment plan for individual patient. The results demonstrated a moderate 
capacity to predict the one-year statin-associated adverse events.  
There are several study limitations. First, some of the clinically important 
predictors were not included due to representation gaps in the claims data, such 
as lab data, BMI, and smoking status. BMI 133 and smoking status 134,135are 
clinically important when predicting statin AEs. However, only 10% of the cohort 
population had this information in claims data. Lab data was excluded from the 
analysis for several reasons: 1) only 30% to 40% of people have any lab results, 
however, the presence of a lab result doesn’t ensure the patients’ lab records are 
complete. In this cohort population, only about 20% patients had lab results. For 
some lab values, such as the creatinine kinase level, less than 1% patients had 
test results; 2) only contains outpatient lab results and most common sample 
types are serum, urine, and blood based tests ; 3) not all outpatient lab test 
results are available; only results that are provided by specific clinical 
laboratories. Therefore, lab results processed outside of these specific clinical 
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laboratories are not available. In addition, this model only focused on older 
population (>40 years of age). Furthermore, our models were built based on 
combination of all types of AEs. Models for specific AEs have not yet been 
investigated since some of the AEs were very rare. In our cohort population, only 
43 patients had rhabdomyolysis and 24 patients had poisoning events. It’s not 
possible to build adequate models based on such small sample size. 
5.5 Conclusion 
Machine learning technologies were applied to develop predictive models 
to predict statin adverse events in CVD patients. In this feasibility study, the 
predictive model had a moderate performance with an AUC ROC of 0.70. This 
model has the potential to be applied to a clinical decision support system to help 




Chapter 6 Summary and future directions 
Statin associated adverse events is the primary reason for statin 
discontinuation. The consequence is that important clinical and treatment 
benefits of statin use for lowering plasma cholesterol levels (and therefore risk of 
primary and secondary cardiovascular events) are frequently lost due to 
discontinuance of statin treatment following occurrence of AEs, leading to 
increased cholesterol levels and increased cardiovascular events. This 
dissertation investigated statin associated adverse events in three aspects: AEs 
risk evaluation in CVD patients who initiated statin agent for secondary 
prevention, simvastatin drug-drug interactions, and adverse events prediction. 
OLDW claims data was used as the data source to do the secondary data 
analysis which is a growing trend and is an important resource for population-
based healthcare research. 
The first part demonstrated how the cohort population was extracted and 
how this cohort was used to investigate specific adverse events in all CVD statin 
users. The descriptive analysis of demographic and other characteristics were 
done for each statin agent group and each statin tolerance group (continuous, 
discontinued, and dropout). Incidence rates were calculated for each adverse 
event stratified by statin agents and statin tolerance groups. 
The second part investigated drug-drug interactions focused on 
simvastatin. Comparisons between DDI group and Non-DDI group and among 
the three time periods within DDI group were conducted. This study analyzed the 
effect of CYP3A4 and/or OATP1B1 inhibitors on simvastatin. 
	 89	
 
The last part discussed how the predictive models were developed to 
predict the up to one-year risk of statin-associated adverse events for CVD 
patients. The performances were compared among five machine learning 
algorithms. SVM was selected as the final optimal model which had a moderate 
predictive ability with an AUC ROC of 0.69 on a set of unseen data.  
In the future, adult patients from 18 to 40 years of age should be included 
to increase the generalizability of the results of the predictive model,. Other large-
scale databases may be considered as well. If possible, the combination of 
multiple healthcare databases is also a good way to increase the sample size, 
obtain a wider range of population, and make the results more generalizable.  
Model accuracy is expected to be further improved. Several ways can be 
considered including adding more years of data and more potentially important 
predictors (e.g., lab data and BMI) by linking with the EHR data. In addition, deep 
learning, as a subset of machine learning, becomes more and more popular 
because it outperforms other methods in many domains. Most of the deep 
learning models are based on the artificial neural networks. Feature selection is 
embedded in the learning process, so domain expertise is less needed and 
irrelevant variables will have very small impacts on the prediction. Another 
important reason to use deep learning is that complex interactions among 
multiple variables are naturally included in the prediction model (consequently, 
the model predicts using many interactive layers of nodes and functions). Using 
deep learning techniques on our dataset may achieve higher accuracy since they 
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have improved classification ability and model accuracy. More outcomes will be 
considered in the future study. A deep-learning model will predict both statin 
associated adverse events and statin discontinuation. A more functional platform 
will be developed to identify the optimal statin treatment plans that not only 
reduce risk of adverse events, but also optimize LDL reduction and reduce statin 
discontinuation for a given patient profile. This platform could be potentially 
applied to a clinical decision support system to provide personalized statin 
treatment plans, minimize the risk of adverse events, and potentially improve 
statin adherence. Knowing which patients are at higher risk of adverse effects of 
statin therapy is valuable. The patient-specific estimated risk could be displayed 
in the EHR within the normal workflow of a clinic or hospital. An alert generated 
by a clinical decision support application in an EHR could assist healthcare 
providers to identify high-risk patients at the point of care, efficiently make a 
decision on appropriate therapy, and prompt a nursing protocol that included 
patient education, follow-up phone calls, and more frequent clinic visits during the 
statin therapy period. Any patient at a certain threshold of risk could be 
automatically placed on the protocol to improve early identification of problems 
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Supplementary Table 1. Advantages and disadvantages of classification methods 
 
Models Advantages Disadvantages 
GLM 1. Response variable does not need to have a 
normal distribution. 
2. Have more flexibility in modeling because 
the choice of link is separate from the 
probability distribution of the response 
variable. 
1. Response variable must be 
independent. 
SVM 1. High computational complexity for building 
model. Effective in high dimensional spaces.  
2. It is memory efficient because of using a 
subset of training points (support vectors) to 
train model. 
3. Different kernel function can be applied to fit 
different situations. 
4. It find the global optimal of the objective 
function by using efficient algorithms.  
5. Overfitting is addressed by maximizing the 
margin of the decision boundary.  
6. Robust to noise. 
1. SVMs do not directly provide 
probability estimates.  
2. Difficult to handle missing 
values.  
3. Difficult to explain. 
Decision tree 1. Computationally inexpensive to construct a 
model and can make a quick prediction on 
new data even when the size of training set 
is large.  
2. It does not make any assumptions on the 
data distribution.  
3. Tree structure can visually represent the 
1. Cannot handle missing values. 
2. Overfitting is a common 
problem. It cannot guarantee to 
return the globally optimal 
decision tree since it only 
makes locally optimal decisions 
at each node.  
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whole process of decision making which 
makes it easy to interpret and explain. 
4. Able to handle both numerical and 
categorical data.  
5. Can handle redundant and irrelevant 
features. 
3. It creates biased trees if some 
classes dominate. Therefore, 
we need to balance the dataset 
prior to fitting with the decision 
tree. 
Random forest 1. Runs efficiently on large databases.  
2. Can effectively handle large missing data.  
3. It has methods to handle unbalanced 
datasets.  
4. The correlation between trees is avoided 
since a subset of the features is selected for 
splitting at each node. Thus, the local 
optimal problem of decision tree can be 
avoided.  
5. Variance of individual tree can be reduced in 
random forest by taking the majority votes 
form all trees. 
6. Can handle redundant and irrelevant 
features. 
1. Sensitive to noisy data. Unlike 
decision trees, results are 
difficult to interpret. 
 
 
ANN 1. It can handle redundant features because 
the weights are automatically learned during 
the training step and tend to be very small 
for redundant features. 
2. Can handle irrelevant features. 
 
 
1. Results may be more difficult to 
interpret.  
2. Cannot handle missing values.  
3. Sensitive to the presence of 
noise in the training data.  
4. It is a time consuming process, 
especially when the number of 
hidden nodes is large.  
5. Tends to find only locally 
optimum solutions. 
Note:  GLM = generalized linear model 
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SVM = support vector machine 
ANN = artificial neural network 
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Supplementary Table 2 List of medical codes used to identify CVD events 
 
CVD Events ICD-9-CM Codes HCPCS Codes 
Acute myocardial 
infarction (AMI) 
410.01, 410.11, 410.21, 
410.31, 410.41, 410.51, 
410.61, 410.71, 410.81, 
410.91 
 
Unstable Angina 411.81  
Coronary artery disease 414.0, 414.01, 414.02, 
414.04, 414.05, 414.2, 
414.3, 414.4, 414.8 
 
Stroke 433.11, 433.21, 433.31, 
433.81, 433.91, 434.01, 






00.66, 36.06, 36.07 
 
92973, 92974, 92975, 
92978, 92979, 92980, 
92981, 92982, 92984, 
92995, 92996, G0290, 
G0291 
Coronary artery bypass 
graft surgery (CABG) 
 
36.1, 36.10, 36.11, 
36.12, 36.13, 36.14, 
36.15, 36.16, 36.17, 
36.19, 36.2 
33510, 33511, 33512, 
33513, 33514, 33516, 
33517, 33518, 33519, 
33521, 33522, 33523, 
33533, 33534, 33535, 
33536, S2205, S2206, 






Supplementary Table 3 74 Extracted features 
	
Category Number of 
features 
Examples 
Patient information 7 Age, gender, home ownership, health 
insurance type1, region, Charlson 
comorbidity score, Elixhauser 
comorbidity score 
Prescription information 10 Atorvastatin drug strength, fluvastatin 
drug strength, lovastatin drug 
strength, pitavastatin drug strength, 
pravastatin drug strength, rosuvastatin 
drug strength, simvastatin drug 
strength, statin exposure time, 
formulary drug, mail order 
Cost  3 Medical costs (first 30 days) 2, health 
plan paid statin costs (per 30 days), 
statin out-of-pocket cost (per 30 days) 
Others 7 Initiation gap3, prescriber specialty, 
transferred claim4, preferred benefits5, 
capitation status6, inpatient CVD 
claim7, outpatient or office visit CVD 
claim8 
Comorbidities 47 17 Charlson comorbidities (see 
supplementary table 6),  
30 Elixhauser comorbidities (see 
supplementary table 7) 
Note:  
1. Health insurance type: commercial or Medicare Advantage; 
2. Medical cost (first 30 days): total cost of health plan paid and patient out-of-
pocket cost for the first 30 days since CVD index date; 
3. Initiation gap is the gap between statin index date and CVD index date; 
4. Transferred claim: discharge status. Discharged and transferred such as home, 
nursing facility, and other places; 
5. Preferred benefits: preferred level of reimbursement on the claim; 
6. Capitation status: identifies if the service is fee-for-service or capitated. 
7. Inpatient CVD claims: CVD inpatient claim(s) on CVD index date or the 
following 2 days; 
8. Outpatient or office visit CVD claim: Only had outpatient or office visit CVD 
claims on CVD index date without any CVD claims (inpatient/outpatient/office 
visits) on CVD index date and the following 90 days. 
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Supplementary Table 4. Performance of single features 
 
Order Features 
1-10 Age, Charlson comorbidity score, initiation gap, statin exposure 
time, health insurance type, Elixhauser comorbidity score, statin 
out-of-pocket cost, medical cost, gender, Hypertension 
11-20 inpatient CVD claim, preferred benefits, prescriber specialty, 
chronic pulmonary disease (Charlson), fluid and electrolyte 
disorders, chronic pulmonary disease, deficiency anemia, renal 
disease (Charlson), diabetes (uncomplicated), Diabetes without 
chronic complication (Charlson) 
21-30 Renal failure, other neurological disorders, peripheral vascular 
disease (Charlson), hypothyroidism, peripheral vascular disorders, 
outpatient or office visit CVD claim, region, congestive heart failure 
(Charlson), depression, congestive heart failure 
31-40 Diabetes (complicated), cerebrovascular disease (Charlson), 
cardiac arrhythmias, rheumatoid arthritis/collagen vascular 
diseases, diabetes with chronic complication (Charlson), drug 
formulary, simvastatin drug strength, cancer (Charlson), mild liver 
disease (Charlson), Psychoses 
41-50 Solid tumor without metastasis, rosuvastatin drug strength, 
rheumatic disease (Charlson), weight loss, valvular disease, 
pulmonary circulation disorders, obesity, mail order, coagulopathy, 
dementia (Charlson), 
51-60 Liver disease, drug abuse, blood loss anemia, paralysis, 
lymphoma, atorvastatin drug strength, transferred claim, lovastatin 
drug strength, hemiplegia or paraplegia (Charlson), metastatic 
cancer 
61-70 Metastatic solid tumor (Charlson), myocardial infarction 
(Charlson), home ownership, moderate or severe liver disease 
(Charlson), alcohol abuse, peptic ulcer disease (Charlson), 
fluvastatin drug strength, pitavastatin drug strength, capitation, 
peptic ulcer disease excluding bleeding, 
71-74 AIDS/HIV, AIDS/HIV (Charlson), health plan paid statin cost, 





Supplementary Table 5. Features selected by forward selection and clinical 
expert 
	
 Forward Feature 




Age √ √ 
Gender √ √ 
Charlson comorbidity score √ √ 
Statin exposure time √ √ 
Health insurance type √ √ 
Medical cost √ √ 
Statin initiation gap √ √ 
Prescriber specialty √ √ 
Region √  
Mail order √  
Drug formulary √ √ 
Statin out-of-pocket cost √ √ 
Simvastatin drug strength √ √ 
Lovastatin drug strength √ √ 
Fluvastatin drug strength √ √ 
Atorvastatin drug strength  √ 
Pitavastatin drug strength  √ 
Pravastatin drug strength  √ 
Rosuvastatin drug strength   
Preferred benefits √ √ 
Inpatient CVD claim √ √ 
Transferred claim √  
Home ownership  √ 
Capitation status  √ 
Fluid and electrolyte 
disorders √ √ 
Rheumatoid arthritis/collagen 
vascular diseases √  
Metastatic cancer √  
Other neurological disorders √  
Renal failure √ √ 
Psychoses √ √ 
Deficiency anemia √ √ 
Cerebrovascular disease √  
Hypothyroidism √  
Weight loss √ √ 
Paralysis √  
Lymphoma √  
Depression √ √ 
Solid tumor without √  
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metastasis 
Alcohol abuse  √ 
Congestive heart failure  √ 
Coagulopathy  √ 
Drug abuse  √ 
Liver disease  √ 
Pulmonary circulation 
disease  √ 
Mild liver disease (Charlson) √  
Cancer (Charlson) √  
Diabetes with chronic 
complication (Charlson) √  
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Supplementary Table 6. ICD-9-CM coding algorithms and weights for Charlson 
comorbidities 
 
Comorbidities ICD-9-CM Weights 
Myocardial infarction 410.x, 412.x 1 
Congestive heart failure 398.91, 402.01, 402.11, 402.91, 
404.01, 404.03, 





093.0, 437.3, 440.x, 441.x, 443.1-
443.9, 447.1, 
1 
 557.1, 557.9, V43.4  
Cerebrovascular disease 362.34, 430.x-438.x 1 
Dementia 290.x, 294.1, 331.2 1 
Chronic pulmonary 
disease 
416.8, 416.9, 490.x-505.x, 506.4, 
508.1, 508.8 
1 
Rheumatic disease 446.5, 710.0-710.4, 714.0-714.2, 
714.8, 725.x 
1 
Peptic ulcer disease 531.x-534.x 1 
Mild liver disease 070.22, 070.23, 070.32, 070.33, 
070.44, 070.54, 
1 




Diabetes without chronic 
complication 
250.0-250.3, 250.8, 250.9 1 
  
Diabetes with chronic 
complication 
250.4-250.7 2 
Hemiplegia or paraplegia 334.1, 342.x, 343.x, 344.0-344.6, 
344.9 
2 
Renal disease 403.01, 403.11, 403.91, 404.02, 
404.03, 404.12, 
404.13, 404.92, 404.93, 582.x, 
583.0-583.7, 585.x, 
2 
 586.x, 588.0, V42.0, V45.1, V56.x  
Any malignancy, 
including lymphoma and 
leukemia, except 







Moderate or severe liver 
disease 
456.0-456.2, 572.2-572.8 3 
Metastatic solid tumor 196.x-199.x 6 
AIDS/HIV 042.x-044.x 6 
 
Note: Comorbidities were identified based on occurrence of at least one 
inpatient diagnose or two outpatient diagnoses. Each comorbidity category is 
assigned a weight (1, 2, 3, or 6) according to their potential influence on 
mortality. The sum of all the weights results in a single comorbidity score - the 
Charlson comorbidity score for a patient to predict the outcome and risk of death 
from many comorbid diseases. A score of zero indicates that no comorbidities 
were found. The higher the score, the more likely the predicted outcome will 
result in mortality. 
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Supplementary Table 7. ICD-9-CM coding algorithms and weights for 
Elixhauser comorbidities 
 
Comorbidities ICD-9-CM Weights 
Congestive heart failure 398.91, 402.11, 402.91, 404.11, 
404.13, 404.91, 404.93, 428.x 
7 
Cardiac arrhythmias 426.10, 426.11, 426.13, 426.2-
426.53, 426.6-426.8, 427.0, 427.2, 
427.31, 427.60, 427.9, 785.0, V45.0, 
V53.3 
5 
Valvular disease 093.2, 394.0-397.1, 424.0-424.91, 




416.x, 417.9 4 
Peripheral vascular 
disorders 
440.x, 441.2, 441.4, 441.7, 441.9, 
443.1-443.9, 447.1, 557.1, 557.9, 
V43.4 
2 
Hypertension,  401.1, 401.9, 402.10, 402.90, 404.10, 
404.90, 405.1, 405.9 
0 
Paralysis 342.0, 342.1, 342.9-344.x 7 
Other neurological 
disorders 
331.9, 332.0, 333.4, 333.5, 334.x, 
335.x, 340.x, 341.1-341.9, 345.0, 
345.1, 345.4, 345.5, 345.8, 345.9, 
348.1, 348.3, 780.3, 784.3 
6 
Chronic pulmonary disease 490-492.8, 493.00-493.91, 494.x-
505.x, 506.4 
3 
Diabetes, uncomplicated 250.0-250.3 0 
Diabetes, complicated 250.4-250.7, 250.9 0 
Hypothyroidism 243-244.2, 244.8, 244.9 0 
Renal failure 403.11, 403.91, 404.12, 404.92, 
585.x, 586.x, V42.0, V45.1, V56.0, 
V56.8 
5 
Liver disease 070.32, 070.33, 070.54, 456.0, 456.1, 
456.2, 571.0, 571.2-571.9, 572.3, 
572.8, V42.7 
11 
Peptic ulcer disease 
excluding bleeding 
531.70, 531.90, 532.70, 532.90, 
533.70, 533.90, 534.70, 534.90, 
V12.71 
0 
AIDS/HIV 042.x–044.x 0 
Lymphoma 200.x–202.3x, 202.5–203.0, 203.8, 
238.6, 273.3, V10.71, V10.72, V10.79 
9 
Metastatic cancer 196.x–199.x 12 
Solid tumor without 
metastasis 
140.x–172.x, 174.x, 175.x, 
179.x–195.x, V10.x 
4 




Coagulopathy 286.x, 287.1, 287.3–287.5 3 
Obesity 278.0 4 
Weight loss 260.x–263.x 6 
Fluid and electrolyte 
disorders 
276.x 5 
Blood loss anemia 280.0 -2 
Deficiency anemia 280.1–281.9, 285.9 -2 
Alcohol abuse 291.1, 291.2, 291.5–291.9, 
303.9, 305.0, V113 
0 
Drug abuse 292.0, 292.82–292.89, 292.9, 
304.0, 305.2–305.9 
7 
Psychoses 295.x–298.x, 299.1 0 
Depression 300.4, 301.12, 309.0, 309.1, 
311 
3 
Note: Comorbidities were identified based on occurrence of at least one 
inpatient diagnose or two outpatient diagnoses. Each comorbidity category is 
assigned a weight from -2 to 12 according to their potential influence on 
mortality. The sum of all the weights results in a single comorbidity score - the 
Elixhauser comorbidity score for a patient to predict the outcome and risk of 
death from many comorbid diseases. The higher the score, the more likely the 




Supplementary Figure 1. Demonstration of key dates, index dates, and time 
periods. 
 
